-
1
-
-
3042634240
-
Tyrosine kinase inhibitors in cancer therapy
-
Madhusudan, S.; Ganesan, T.S. Tyrosine kinase inhibitors in cancer therapy. Clin. Biochem., 2004, 37 (7), 618-635.
-
(2004)
Clin. Biochem
, vol.37
, Issue.7
, pp. 618-635
-
-
Madhusudan, S.1
Ganesan, T.S.2
-
2
-
-
0037032835
-
The protein kinase complement of the human genome
-
Manning, G.; Whyte, D.B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science, 2002, 298 (5600), 1912.
-
(2002)
Science
, vol.298
, Issue.5600
, pp. 1912
-
-
Manning, G.1
Whyte, D.B.2
Martinez, R.3
Hunter, T.4
Sudarsanam, S.5
-
3
-
-
84869237379
-
Mechanisms of acquired resistance to tyrosine kinase inhibitors
-
Chen, Y.; Fu, L. Mechanisms of acquired resistance to tyrosine kinase inhibitors. Acta Pharm. sin. B, 2011, 1 (4), 197-207.
-
(2011)
Acta Pharm. Sin. B
, vol.1
, Issue.4
, pp. 197-207
-
-
Chen, Y.1
Fu, L.2
-
4
-
-
0037130294
-
Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1
-
Hegedus, T.; Orfi, L.; Sepro di, A.; Váradi, A.; Sarkadi, B.; Kéri, G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochem. Biophys. Acta Mol. Basis Dis., 2002, 1587 (2-3), 318-325.
-
(2002)
Biochem. Biophys. Acta Mol. Basis Dis
, vol.1587
, Issue.2-3
, pp. 318-325
-
-
Hegedus, T.1
Orfi, L.2
di Sepro, A.3
Váradi, A.4
Sarkadi, B.5
Kéri, G.6
-
5
-
-
78649719727
-
Targeting non-malignant disorders with tyrosine kinase inhibitors
-
Grimminger, F.; Schermuly, R.T.; Ghofrani, H.A. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat. Rev. Drug Discov., 2010, 9 (12), 956-970.
-
(2010)
Nat. Rev. Drug Discov
, vol.9
, Issue.12
, pp. 956-970
-
-
Grimminger, F.1
Schermuly, R.T.2
Ghofrani, H.A.3
-
6
-
-
15944404601
-
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
-
Deininger, M.; Buchdunger, E.; Druker, B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood, 2005, 105 (7), 2640-2653.
-
(2005)
Blood
, vol.105
, Issue.7
, pp. 2640-2653
-
-
Deininger, M.1
Buchdunger, E.2
Druker, B.J.3
-
7
-
-
4644318882
-
Tyrosine kinase inhibitors in renal cell carcinoma
-
Potti, A.; George, D.J. Tyrosine kinase inhibitors in renal cell carcinoma. Clin. Cancer Res., 2004, 10 (18), 6371S-6376S.
-
(2004)
Clin. Cancer Res
, vol.10
, Issue.18
-
-
Potti, A.1
George, D.J.2
-
8
-
-
0142055937
-
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer
-
Kris, M.G.; Natale, R.B.; Herbst, R.S.; Lynch, T.J.; Prager, D.; Belani, C.P.; Schiller, J.H.; Kelly, K.; Spiridonidis, H.; Sandler, A. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. J. Am. Med. Assoc., 2003, 290 (16), 2149.
-
(2149)
J. Am. Med. Assoc
, vol.290
, Issue.16
, pp. 2003
-
-
Kris, M.G.1
Natale, R.B.2
Herbst, R.S.3
Lynch, T.J.4
Prager, D.5
Belani, C.P.6
Schiller, J.H.7
Kelly, K.8
Spiridonidis, H.9
Sandler, A.10
-
9
-
-
85047696958
-
ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinaseinhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model
-
Williams, K.; Telfer, B.; Stratford, I.; Wedge, S. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinaseinhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br. J. Cancer, 2002, 86 (7), 1157-1161.
-
(2002)
Br. J. Cancer
, vol.86
, Issue.7
, pp. 1157-1161
-
-
Williams, K.1
Telfer, B.2
Stratford, I.3
Wedge, S.4
-
10
-
-
0036527429
-
Protein kinases-the major drug targets of the twenty-first century?
-
Cohen, P. Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug Discov., 2002, 1 (4), 309-315.
-
(2002)
Nat. Rev. Drug Discov
, vol.1
, Issue.4
, pp. 309-315
-
-
Cohen, P.1
-
12
-
-
84862103506
-
Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
-
Broekman, F.; Giovannetti, E.; Peters, G.J. Tyrosine kinase inhibitors: Multi-targeted or single-targeted? World J. Clin. Oncol., 2011, 2 (2), 80.
-
(2011)
World J. Clin. Oncol
, vol.2
, Issue.2
, pp. 80
-
-
Broekman, F.1
Giovannetti, E.2
Peters, G.J.3
-
13
-
-
0033786922
-
Protein tyrosine kinase structure and function
-
Hubbard, S.R.; Till, J.H. Protein tyrosine kinase structure and function. Annu. Rev. Biochem., 2000, 69 (1), 373-398.
-
(2000)
Annu. Rev. Biochem
, vol.69
, Issue.1
, pp. 373-398
-
-
Hubbard, S.R.1
Till, J.H.2
-
14
-
-
47349101284
-
The role of insulin receptors and IGF-1 receptors in cancer and other diseases
-
Frasca, F.; Pandini, G.; Sciacca, L.; Pezzino, V.; Squatrito, S.; Belfiore, A.; Vigneri, R.; The role of insulin receptors and IGF-1 receptors in cancer and other diseases. Arch. Physiol. Biochem., 2008, 114 (1), 23-37.
-
(2008)
Arch. Physiol. Biochem
, vol.114
, Issue.1
, pp. 23-37
-
-
Frasca, F.1
Pandini, G.2
Sciacca, L.3
Pezzino, V.4
Squatrito, S.5
Belfiore, A.6
Vigneri, R.7
-
15
-
-
0036970842
-
The role of the IGF system in cancer: From basic to clinical studies and clinical applications
-
Moschos, S.J.; Mantzoros, C.S. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology, 2002, 63 (4), 317-332.
-
(2002)
Oncology
, vol.63
, Issue.4
, pp. 317-332
-
-
Moschos, S.J.1
Mantzoros, C.S.2
-
16
-
-
33846874575
-
The role of the IGF system in cancer growth and metastasis: Overview and recent insights
-
Samani, A.A.; Yakar, S.; LeRoith, D.; Brodt, P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev., 2007, 28 (1), 20-47.
-
(2007)
Endocr. Rev
, vol.28
, Issue.1
, pp. 20-47
-
-
Samani, A.A.1
Yakar, S.2
Leroith, D.3
Brodt, P.4
-
17
-
-
0242594016
-
The IGF-1 receptor in cancer biology
-
Baserga, R.; Peruzzi, F.; Reiss, K. The IGF-1 receptor in cancer biology. Int. J. Cancer, 2003, 107 (6), 873-877.
-
(2003)
Int. J. Cancer
, vol.107
, Issue.6
, pp. 873-877
-
-
Baserga, R.1
Peruzzi, F.2
Reiss, K.3
-
18
-
-
23044493251
-
Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer
-
Hofmann, F.; García-Echeverría, C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov. Today, 2005, 10 (15), 1041-1047.
-
(2005)
Drug Discov. Today
, vol.10
, Issue.15
, pp. 1041-1047
-
-
Hofmann, F.1
García-Echeverría, C.2
-
19
-
-
85028516874
-
Malaguarnera, R
-
LeRoith, D., Ed.; Springer Science, New York
-
Belfiore, A.; Malaguarnera, R. In: Insulin-like Growth Factors and Cancer; LeRoith, D., Ed.; Springer Science, New York, 2012, pp. 263-278.
-
(2012)
Insulin-like Growth Factors and Cancer
, pp. 263-278
-
-
Belfiore, A.1
-
20
-
-
84857640868
-
The insulin and insulin-like growth factor receptor family in neoplasia: An update
-
Pollak, M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat. Rev. Cancer, 2012, 12, 159-169.
-
(2012)
Nat. Rev. Cancer
, vol.12
, pp. 159-169
-
-
Pollak, M.1
-
23
-
-
79953647468
-
Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer
-
Buck, E.; Mulvihill, M. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Expert Opin. Invest. Drugs, 2011, 20, 605-621.
-
(2011)
Expert Opin. Invest. Drugs
, vol.20
, pp. 605-621
-
-
Buck, E.1
Mulvihill, M.2
-
24
-
-
79959466358
-
Minireview: IGF, insulin, and cancer
-
Gallagher, E.J.; LeRoith, D. Minireview: IGF, insulin, and cancer. Endocrinology, 2011, 152 (7), 2546-2551.
-
(2011)
Endocrinology
, vol.152
, Issue.7
, pp. 2546-2551
-
-
Gallagher, E.J.1
Leroith, D.2
-
25
-
-
0025009815
-
The cysteine-rich domains of the insulin and insulin-like growth factor I receptors are primary determinants of hormone binding specificity. Evidence from receptor chimeras
-
Gustafson, T.; Rutter, W. The cysteine-rich domains of the insulin and insulin-like growth factor I receptors are primary determinants of hormone binding specificity. Evidence from receptor chimeras. J. Biol. Chem., 1990, 265 (30), 18663-18667.
-
(1990)
J. Biol. Chem
, vol.265
, Issue.30
, pp. 18663-18667
-
-
Gustafson, T.1
Rutter, W.2
-
26
-
-
84877831303
-
-
1st ed.; Academic Press: London
-
Litwack, G. Insulin and IGFs, 1st ed.; Academic Press: London, 2009.
-
(2009)
Insulin and IGFs
-
-
Litwack, G.1
-
27
-
-
0024539198
-
Alternative splicing of human insulin receptor messenger RNA
-
Seino, S.; Bell, G.I. Alternative splicing of human insulin receptor messenger RNA. Biochem. Biophys. Res. Commun., 1989, 159 (1), 312-316.
-
(1989)
Biochem. Biophys. Res. Commun
, vol.159
, Issue.1
, pp. 312-316
-
-
Seino, S.1
Bell, G.I.2
-
28
-
-
0032726331
-
Alternative splicing, gene localization, and binding of SH2-B to the insulin receptor kinase domain
-
Nelms, K.; O'Neill, T.J.; Li, S.; Hubbard, S.R.; Gustafson, T.A.; Paul, W.E. Alternative splicing, gene localization, and binding of SH2-B to the insulin receptor kinase domain. Mamm. Genome, 1999, 10 (12), 1160-1167.
-
(1999)
Mamm. Genome
, vol.10
, Issue.12
, pp. 1160-1167
-
-
Nelms, K.1
O'Neill, T.J.2
Li, S.3
Hubbard, S.R.4
Gustafson, T.A.5
Paul, W.E.6
-
29
-
-
20444411501
-
Characterization of the functional insulin binding epitopes of the full-length insulin receptor
-
Whittaker, J.; Whittaker, L. Characterization of the functional insulin binding epitopes of the full-length insulin receptor. J. Biol. Chem., 2005, 280 (22), 20932.
-
(2005)
J. Biol. Chem
, vol.280
, Issue.22
, pp. 20932
-
-
Whittaker, J.1
Whittaker, L.2
-
30
-
-
0024403208
-
Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man
-
Moller, D.E.; Yokota, A.; Caro, J.F.; Flier, J.S. Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Mol. Endocrinol., 1989, 3 (8), 1263-1269.
-
(1989)
Mol. Endocrinol
, vol.3
, Issue.8
, pp. 1263-1269
-
-
Moller, D.E.1
Yokota, A.2
Caro, J.F.3
Flier, J.S.4
-
31
-
-
34247872895
-
Characterization of insulin/IGF hybrid receptors: Contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation
-
Benyoucef, S.; Surinya, K.H.; Hadaschik, D.; Siddle, K. Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation. Biochem. J., 2007, 403 (Pt 3), 603.
-
(2007)
Biochem. J
, vol.403
, Issue.Pt 3
, pp. 603
-
-
Benyoucef, S.1
Surinya, K.H.2
Hadaschik, D.3
Siddle, K.4
-
32
-
-
0031009430
-
Alanine scanning mutagenesis of insulin
-
Kristensen, C.; Kjeldsen, T.; Wiberg, F.C.; Schäffer, L.; Hach, M.; Havelund, S.; Bass, J.; Steiner, D.F.; Andersen, A.S. Alanine scanning mutagenesis of insulin. J. Biol. Chem., 1997, 272 (20), 12978-12983.
-
(1997)
J. Biol. Chem
, vol.272
, Issue.20
, pp. 12978-12983
-
-
Kristensen, C.1
Kjeldsen, T.2
Wiberg, F.C.3
Schäffer, L.4
Hach, M.5
Havelund, S.6
Bass, J.7
Steiner, D.F.8
Andersen, A.S.9
-
33
-
-
0029553646
-
Localization of specific amino acids contributing to insulin specificity of the insulin receptor
-
Andersen, A.S.; Wiberg, F.C.; Kjeldsen, T. Localization of specific amino acids contributing to insulin specificity of the insulin receptor. Ann. N. Y. Acad. Sci., 1995, 766 (1), 466-468.
-
(1995)
Ann. N. Y. Acad. Sci
, vol.766
, Issue.1
, pp. 466-468
-
-
Andersen, A.S.1
Wiberg, F.C.2
Kjeldsen, T.3
-
34
-
-
0030756092
-
Identification of common ligand binding determinants of the insulin and insulin-like growth factor 1 receptors
-
Mynarcik, D.C.; Williams, P.F.; Schaffer, L.; Yu, G.Q.; Whittaker, J. Identification of common ligand binding determinants of the insulin and insulin-like growth factor 1 receptors. J. Biol. Chem., 1997, 272 (30), 18650.
-
(1997)
J. Biol. Chem
, vol.272
, Issue.30
, pp. 18650
-
-
Mynarcik, D.C.1
Williams, P.F.2
Schaffer, L.3
Yu, G.Q.4
Whittaker, J.5
-
35
-
-
0022800838
-
Insulin-like growth factor I receptor primary structure: Comparison with insulin receptor suggests structural determinants that define functional specificity
-
Ullrich, A.; Gray, A.; Tam, A.W.; Yang-Feng, T.; Tsubokawa, M.; Collins, C.; Henzel, W.; Le Bon, T.; Kathuria, S.; Chen, E. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J., 1986, 5 (10), 2503.
-
(1986)
EMBO J
, vol.5
, Issue.10
, pp. 2503
-
-
Ullrich, A.1
Gray, A.2
Tam, A.W.3
Yang-Feng, T.4
Tsubokawa, M.5
Collins, C.6
Henzel, W.7
Le Bon, T.8
Kathuria, S.9
Chen, E.10
-
36
-
-
0018650525
-
Insulin-binding sites in the rat brain: In vivo localization to the circumventricular organs by quantitative radioautography
-
Houten, M.V.A.N.; Posner, B.I.; Kopriwa, B.M.; Brawer, J.R. Insulin-binding sites in the rat brain: in vivo localization to the circumventricular organs by quantitative radioautography. Endocrinology, 1979, 105 (3), 666.
-
(1979)
Endocrinology
, vol.105
, Issue.3
, pp. 666
-
-
Houten, M.V.A.N.1
Posner, B.I.2
Kopriwa, B.M.3
Brawer, J.R.4
-
37
-
-
0035941231
-
Alanine scanning mutagenesis of a type 1 insulin-like growth factor receptor ligand binding site
-
Whittaker, J.; Groth, A.V.; Mynarcik, D.C.; Pluzek, L.; Gadsbøll, V.L.; Whittaker, L.J. Alanine scanning mutagenesis of a type 1 insulin-like growth factor receptor ligand binding site. J. Biol. Chem., 2001, 276 (47), 43980-43986.
-
(2001)
J. Biol. Chem
, vol.276
, Issue.47
, pp. 43980-43986
-
-
Whittaker, J.1
Groth, A.V.2
Mynarcik, D.C.3
Pluzek, L.4
Gadsbøll, V.L.5
Whittaker, L.J.6
-
38
-
-
0035185571
-
Structure and autoregulation of the insulin-like growth factor 1 receptor kinase
-
Favelyukis, S.; Till, J.H.; Hubbard, S.R.; Miller, W.T. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat. Struct. Mol. Biol., 2001, 8 (12), 1058-1063.
-
(2001)
Nat. Struct. Mol. Biol
, vol.8
, Issue.12
, pp. 1058-1063
-
-
Favelyukis, S.1
Till, J.H.2
Hubbard, S.R.3
Miller, W.T.4
-
39
-
-
0028214152
-
Role of the carboxyl-terminal domains of the insulin and insulin-like growth factor I receptors in receptor function
-
Faria, T.N.; Blakesley, V.A.; Kato, H.; Stannard, B.; LeRoith, D.; Roberts, C. Role of the carboxyl-terminal domains of the insulin and insulin-like growth factor I receptors in receptor function. J. Biol. Chem., 1994, 269 (19), 13922.
-
(1994)
J. Biol. Chem
, vol.269
, Issue.19
, pp. 13922
-
-
Faria, T.N.1
Blakesley, V.A.2
Kato, H.3
Stannard, B.4
Leroith, D.5
Roberts, C.6
-
40
-
-
0037064032
-
Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase
-
Munshi, S.; Kornienko, M.; Hall, D.L.; Reid, J.C.; Waxman, L.; Stirdivant, S.M.; Darke, P.L.; Kuo, L.C. Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase. J. Biol. Chem., 2002, 277 (41), 38797-38802.
-
(2002)
J. Biol. Chem
, vol.277
, Issue.41
, pp. 38797-38802
-
-
Munshi, S.1
Kornienko, M.2
Hall, D.L.3
Reid, J.C.4
Waxman, L.5
Stirdivant, S.M.6
Darke, P.L.7
Kuo, L.C.8
-
41
-
-
2942587068
-
Inhibition of insulin-like growth factor I receptor autophosphorylation by novel 6-5 ring-fused compounds
-
Li, W.; Favelyukis, S.; Yang, J.; Zeng, Y.; Yu, J.; Gangjee, A.; Miller, W.T. Inhibition of insulin-like growth factor I receptor autophosphorylation by novel 6-5 ring-fused compounds. Biochem. Pharmacol., 2004, 68 (1), 145-154.
-
(2004)
Biochem. Pharmacol
, vol.68
, Issue.1
, pp. 145-154
-
-
Li, W.1
Favelyukis, S.2
Yang, J.3
Zeng, Y.4
Yu, J.5
Gangjee, A.6
Miller, W.T.7
-
42
-
-
0032470252
-
The insulin receptor--a critical link in glucose homeostasis and insulin action
-
Patti, M.E.; Kahn, C.R. The insulin receptor--a critical link in glucose homeostasis and insulin action. J. Basic Clin. Physiol. Pharmacol., 1998, 9 (2-4), 89.
-
(1998)
J. Basic Clin. Physiol. Pharmacol
, vol.9
, Issue.2-4
, pp. 89
-
-
Patti, M.E.1
Kahn, C.R.2
-
43
-
-
0021813187
-
Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man
-
Matthews, D.; Hosker, J.; Rudenski, A.; Naylor, B.; Treacher, D.; Turner, R. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985, 28 (7), 412-419.
-
(1985)
Diabetologia
, vol.28
, Issue.7
, pp. 412-419
-
-
Matthews, D.1
Hosker, J.2
Rudenski, A.3
Naylor, B.4
Treacher, D.5
Turner, R.6
-
44
-
-
22044434446
-
Role of insulin-like growth factor 1 receptor signalling in cancer
-
Larsson, O.; Girnita, A.; Girnita, L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br. J. Cancer, 2005, 92 (12), 2097-2101.
-
(2005)
Br. J. Cancer
, vol.92
, Issue.12
, pp. 2097-2101
-
-
Larsson, O.1
Girnita, A.2
Girnita, L.3
-
45
-
-
84867420359
-
Insulin resistance and cancer: Epidemiological evidence
-
Inoue, M.; Tsugane, S. Insulin resistance and cancer: epidemiological evidence. Endocr. Relat. Cancer, 2012, 19 (5), F1-F8.
-
(2012)
Endocr. Relat. Cancer
, vol.19
, Issue.5
-
-
Inoue, M.1
Tsugane, S.2
-
46
-
-
34047174592
-
The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer
-
Belfiore, A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr. Pharm. Des., 2007, 13 (7), 671-686.
-
(2007)
Curr. Pharm. Des
, vol.13
, Issue.7
, pp. 671-686
-
-
Belfiore, A.1
-
47
-
-
0031041425
-
Role of the IGF-I receptor in mutagenesis and tumor promotion
-
Blakesley, V.; Stannard, B.; Kalebic, T.; Helman, L.; LeRoith, D. Role of the IGF-I receptor in mutagenesis and tumor promotion. J. Endocrinol., 1997, 152 (3), 339.
-
(1997)
J. Endocrinol
, vol.152
, Issue.3
, pp. 339
-
-
Blakesley, V.1
Stannard, B.2
Kalebic, T.3
Helman, L.4
Leroith, D.5
-
48
-
-
0029913170
-
Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells
-
Steller, M.A.; Delgado, C.H.; Bartels, C.J.; Woodworth, C.D.; Zou, Z. Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res., 1996, 56 (8), 1761.
-
(1996)
Cancer Res
, vol.56
, Issue.8
, pp. 1761
-
-
Steller, M.A.1
Delgado, C.H.2
Bartels, C.J.3
Woodworth, C.D.4
Zou, Z.5
-
49
-
-
77957241580
-
The proliferating role of insulin and insulin-like growth factors in cancer
-
Gallagher, E.J.; LeRoith, D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol. Metab., 2010, 21 (10), 610-618.
-
(2010)
Trends Endocrinol. Metab
, vol.21
, Issue.10
, pp. 610-618
-
-
Gallagher, E.J.1
Leroith, D.2
-
51
-
-
38849088141
-
The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer
-
Ryan, P.D.; Goss, P.E. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist, 2008, 13 (1), 16-24.
-
(2008)
Oncologist
, vol.13
, Issue.1
, pp. 16-24
-
-
Ryan, P.D.1
Goss, P.E.2
-
52
-
-
84864006046
-
Targeting the insulin-like growth factor receptor pathway in lung cancer: Problems and pitfalls
-
Fidler, M.J.; Shersher, D.D.; Borgia, J.A.; Bonomi, P. Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls. Ther. Adv. Med. Oncol., 2012, 4 (2), 51-60.
-
(2012)
Ther. Adv. Med. Oncol
, vol.4
, Issue.2
, pp. 51-60
-
-
Fidler, M.J.1
Shersher, D.D.2
Borgia, J.A.3
Bonomi, P.4
-
53
-
-
79955991871
-
18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer
-
McKinley, E.T.; Bugaj, J.E.; Zhao, P.; Guleryuz, S.; Mantis, C.; Gokhale, P.C.; Wild, R.; Manning, H.C. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin. Cancer Res., 2011, 17 (10), 3332-3340.
-
(2011)
Clin. Cancer Res
, vol.17
, Issue.10
, pp. 3332-3340
-
-
McKinley, E.T.1
Bugaj, J.E.2
Zhao, P.3
Guleryuz, S.4
Mantis, C.5
Gokhale, P.C.6
Wild, R.7
Manning, H.C.8
-
54
-
-
0024550730
-
Analysis of insulin-like growth factor I gene expression in malignancy: Evidence for a paracrine role in human breast cancer
-
Yee, D.; Paik, S.; Lebovic, G.S.; Marcus, R.R.; Favoni, R.E.; Cullen, K.J.; Lippman, M.E.; Rosen, N. Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol. Endocrinol., 1989, 3 (3), 509-517.
-
(1989)
Mol. Endocrinol
, vol.3
, Issue.3
, pp. 509-517
-
-
Yee, D.1
Paik, S.2
Lebovic, G.S.3
Marcus, R.R.4
Favoni, R.E.5
Cullen, K.J.6
Lippman, M.E.7
Rosen, N.8
-
55
-
-
0032499440
-
Circulating concentrations of insulin-like growth factor I and risk of breast cancer
-
Hankinson, S.E.; Willett, W.C.; Colditz, G.A.; Hunter, D.J.; Michaud, D.S.; Deroo, B.; Rosner, B.; Speizer, F.E.; Pollak, M. Circulating concentrations of insulin-like growth factor I and risk of breast cancer. The Lancet, 1998, 351 (9113), 1393-1396.
-
(1998)
The Lancet
, vol.351
, Issue.9113
, pp. 1393-1396
-
-
Hankinson, S.E.1
Willett, W.C.2
Colditz, G.A.3
Hunter, D.J.4
Michaud, D.S.5
Deroo, B.6
Rosner, B.7
Speizer, F.E.8
Pollak, M.9
-
56
-
-
0034788985
-
The IGF system and breast cancer
-
Sachdev, D.; Yee, D. The IGF system and breast cancer. Endocr. Relat. Cancer, 2001, 8 (3), 197-209.
-
(2001)
Endocr. Relat. Cancer
, vol.8
, Issue.3
, pp. 197-209
-
-
Sachdev, D.1
Yee, D.2
-
57
-
-
0033838566
-
Function of the IGF-I receptor in breast cancer
-
Surmacz, E. Function of the IGF-I receptor in breast cancer. J. Mammary Gland Biol. Neoplasia, 2000, 5 (1), 95-105.
-
(2000)
J. Mammary Gland Biol. Neoplasia
, vol.5
, Issue.1
, pp. 95-105
-
-
Surmacz, E.1
-
61
-
-
84857920393
-
Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes
-
Yerushalmi, R.; Gelmon, K.A.; Leung, S.; Gao, D.; Cheang, M.; Pollak, M.; Turashvili, G.; Gilks, B.C.; Kennecke, H. Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Res. Treat., 2012, 132 (1), 131-142.
-
(2012)
Breast Cancer Res. Treat
, vol.132
, Issue.1
, pp. 131-142
-
-
Yerushalmi, R.1
Gelmon, K.A.2
Leung, S.3
Gao, D.4
Cheang, M.5
Pollak, M.6
Turashvili, G.7
Gilks, B.C.8
Kennecke, H.9
-
62
-
-
84855811750
-
Targeting the subtypes of breast cancer: Rethinking investigational drugs
-
Curigliano, G.; Locatelli, M.; Fumagalli, L.; Brollo, J.; Munzone, E.; Nolé, F.; Criscitiello, C.; Goldhirsch, A. Targeting the subtypes of breast cancer: rethinking investigational drugs. Expert Opin. Invest. Drugs, 2012, (2), 1-14.
-
(2012)
Expert Opin. Invest. Drugs
, Issue.2
, pp. 1-14
-
-
Curigliano, G.1
Locatelli, M.2
Fumagalli, L.3
Brollo, J.4
Munzone, E.5
Nolé, F.6
Criscitiello, C.7
Goldhirsch, A.8
-
63
-
-
0029885705
-
Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, and PC-3 cells
-
Kimura, G.; Kasuya, J.; Giannini, S.; Honda, Y.; Mohan, S.; Kawachi, M.; Akimoto, M.; Fujita-Yamaguchi, Y. Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, and PC-3 cells. Int. J. Urol., 1996, 3 (1), 39.
-
(1996)
Int. J. Urol
, vol.3
, Issue.1
, pp. 39
-
-
Kimura, G.1
Kasuya, J.2
Giannini, S.3
Honda, Y.4
Mohan, S.5
Kawachi, M.6
Akimoto, M.7
Fujita-Yamaguchi, Y.8
-
64
-
-
0032540667
-
Insulin-like growth factor 1 and prostate cancer risk: A population-based, casecontrol study
-
Wolk, A.; Bergström, R.; Mantzoros, C.S.; Lagiou, P.; Andersson, S.O.; Signorello, L.B.; Trichopoulos, D.; Adami, H.O. Insulin-like growth factor 1 and prostate cancer risk: a population-based, casecontrol study. J. Natl. Cancer Inst., 1998, 90 (12), 911-915.
-
(1998)
J. Natl. Cancer Inst
, vol.90
, Issue.12
, pp. 911-915
-
-
Wolk, A.1
Bergström, R.2
Mantzoros, C.S.3
Lagiou, P.4
Andersson, S.O.5
Signorello, L.B.6
Trichopoulos, D.7
Adami, H.O.8
-
65
-
-
0030799934
-
Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia
-
Mantzoros, C.; Tzonou, A.; Signorello, L.; Stampfer, M.; Trichopoulos, D.; Adami, H. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br. J. Cancer, 1997, 76 (9), 1115.
-
(1997)
Br. J. Cancer
, vol.76
, Issue.9
, pp. 1115
-
-
Mantzoros, C.1
Tzonou, A.2
Signorello, L.3
Stampfer, M.4
Trichopoulos, D.5
Adami, H.6
-
67
-
-
84862908410
-
Circulating Insulin-Like Growth Factors and IGF-Binding Proteins in PSA-Detected Prostate Cancer: The Large Case-Control Study Protect
-
Rowlands, M.A.; Holly, J.M.P.; Gunnell, D.; Donovan, J.; Lane, J.A.; Hamdy, F.; Neal, D.E.; Oliver, S.; Smith, G.D.; Martin, R.M. Circulating Insulin-Like Growth Factors and IGF-Binding Proteins in PSA-Detected Prostate Cancer: The Large Case-Control Study Protect. Cancer Res., 2012, 72 (2), 503-515.
-
(2012)
Cancer Res
, vol.72
, Issue.2
, pp. 503-515
-
-
Rowlands, M.A.1
Holly, J.M.P.2
Gunnell, D.3
Donovan, J.4
Lane, J.A.5
Hamdy, F.6
Neal, D.E.7
Oliver, S.8
Smith, G.D.9
Martin, R.M.10
-
68
-
-
84860391606
-
Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: A review
-
Ozkan, E.E. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. Mol. Cell. Endocrinol., 2011, 344 (1), 1-24.
-
(2011)
Mol. Cell. Endocrinol
, vol.344
, Issue.1
, pp. 1-24
-
-
Ozkan, E.E.1
-
69
-
-
84864353160
-
Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic origin
-
Gu, P.; Wu, J.; Newman, E.; Muggia, F. Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic origin. Int. J. Heptol., 2012, 2012.
-
(2012)
Int. J. Heptol
, pp. 2012
-
-
Gu, P.1
Wu, J.2
Newman, E.3
Muggia, F.4
-
70
-
-
81055124254
-
Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells
-
Jameson, M.J.; Beckler, A.D.; Taniguchi, L.E.; Allak, A.; VanWagner, L.B.; Lee, N.G.; Thomsen, W.C.; Hubbard, M.A.; Thomas, C.Y. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells. Mol. Cancer Ther., 2011, 10 (11), 2124-2134.
-
(2011)
Mol. Cancer Ther
, vol.10
, Issue.11
, pp. 2124-2134
-
-
Jameson, M.J.1
Beckler, A.D.2
Taniguchi, L.E.3
Allak, A.4
Vanwagner, L.B.5
Lee, N.G.6
Thomsen, W.C.7
Hubbard, M.A.8
Thomas, C.Y.9
-
71
-
-
78650625659
-
A candidate targeting molecule of insulin-like growth factor-I receptor for gastrointestinal cancers
-
Adachi, Y.; Yamamoto, H.; Ohashi, H.; Endo, T.; Carbone, D.P.; Imai, K.; Shinomura, Y. A candidate targeting molecule of insulin-like growth factor-I receptor for gastrointestinal cancers. World J. Gastroentero., 2010, 16 (46), 5779.
-
(2010)
World J. Gastroentero
, vol.16
, Issue.46
, pp. 5779
-
-
Adachi, Y.1
Yamamoto, H.2
Ohashi, H.3
Endo, T.4
Carbone, D.P.5
Imai, K.6
Shinomura, Y.7
-
72
-
-
79956337832
-
Targeting the insulin growth factor pathway in gastrointestinal cancers
-
Golan, T.; Javle, M. Targeting the insulin growth factor pathway in gastrointestinal cancers. Oncology, 2011, 25 (6).
-
(2011)
Oncology
, vol.25
, Issue.6
-
-
Golan, T.1
Javle, M.2
-
73
-
-
0026504138
-
Characterization of insulinlike growth factor I receptors in human colon cancer
-
Guo, Y.; Narayan, S.; Yallampalli, C.; Singh, P. Characterization of insulinlike growth factor I receptors in human colon cancer. Gastroenterology, 1992, 102 (4 Pt 1), 1101.
-
(1992)
Gastroenterology
, vol.102
, Issue.4 Pt 1
, pp. 1101
-
-
Guo, Y.1
Narayan, S.2
Yallampalli, C.3
Singh, P.4
-
74
-
-
0027327503
-
Insulinlike growth factors and binding proteins in colon cancer
-
Singh, P.; Rubin, N. Insulinlike growth factors and binding proteins in colon cancer. Gastroenterology, 1993, 105 (4), 1218.
-
(1993)
Gastroenterology
, vol.105
, Issue.4
, pp. 1218
-
-
Singh, P.1
Rubin, N.2
-
75
-
-
0036173548
-
Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis
-
Wu, Y.; Yakar, S.; Zhao, L.; Hennighausen, L.; LeRoith, D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res., 2002, 62 (4), 1030.
-
(2002)
Cancer Res
, vol.62
, Issue.4
, pp. 1030
-
-
Wu, Y.1
Yakar, S.2
Zhao, L.3
Hennighausen, L.4
Leroith, D.5
-
76
-
-
78349254271
-
The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models
-
Flanigan, S.A.; Pitts, T.M.; Eckhardt, S.G.; Tentler, J.J.; Tan, A.C.; Thorburn, A.; Leong, S. The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models. Clin. Cancer Res., 2010, 16 (22), 5436-5446.
-
(2010)
Clin. Cancer Res
, vol.16
, Issue.22
, pp. 5436-5446
-
-
Flanigan, S.A.1
Pitts, T.M.2
Eckhardt, S.G.3
Tentler, J.J.4
Tan, A.C.5
Thorburn, A.6
Leong, S.7
-
77
-
-
58249092146
-
Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer
-
Wolpin, B.M.; Meyerhardt, J.A.; Chan, A.T.; Ng, K.; Chan, J.A.; Wu, K.; Pollak, M.N.; Giovannucci, E.L.; Fuchs, C.S. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J. Clin. Oncol., 2009, 27 (2), 176-185.
-
(2009)
J. Clin. Oncol
, vol.27
, Issue.2
, pp. 176-185
-
-
Wolpin, B.M.1
Meyerhardt, J.A.2
Chan, A.T.3
Ng, K.4
Chan, J.A.5
Wu, K.6
Pollak, M.N.7
Giovannucci, E.L.8
Fuchs, C.S.9
-
78
-
-
0035160628
-
Insulin, insulin-like growth factors and colon cancer: A review of the evidence
-
Giovannucci, E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J. Nutr., 2001, 131 (11), 3109S-3120S.
-
(2001)
J. Nutr
, vol.131
, Issue.11
-
-
Giovannucci, E.1
-
79
-
-
0346725866
-
The role of the IGF axis in hepatocarcinogenesis
-
Scharf, J.; Braulke, T. The role of the IGF axis in hepatocarcinogenesis. Horm. Metab. Res., 2003, 35 (11-12), 685-693.
-
(2003)
Horm. Metab. Res
, vol.35
, Issue.11-12
, pp. 685-693
-
-
Scharf, J.1
Braulke, T.2
-
80
-
-
77956060553
-
Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma
-
Wu, J.; Henderson, C.; Feun, L.; Van Veldhuizen, P.; Gold, P.; Zheng, H.; Ryan, T.; Blaszkowsky, L.S.; Chen, H.B.; Costa, M. Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. Invest. New Drugs, 2010, 28 (5), 670-676.
-
(2010)
Invest. New Drugs
, vol.28
, Issue.5
, pp. 670-676
-
-
Wu, J.1
Henderson, C.2
Feun, L.3
Van Veldhuizen, P.4
Gold, P.5
Zheng, H.6
Ryan, T.7
Blaszkowsky, L.S.8
Chen, H.B.9
Costa, M.10
-
81
-
-
79959848106
-
Targeting insulin-like growth factor axis in hepatocellular carcinoma
-
Wu, J.; Zhu, A.X. Targeting insulin-like growth factor axis in hepatocellular carcinoma. J. Hematol. Oncol., 2011, 4 (1), 1-11.
-
(2011)
J. Hematol. Oncol
, vol.4
, Issue.1
, pp. 1-11
-
-
Wu, J.1
Zhu, A.X.2
-
82
-
-
84877812001
-
Predictive Biomarkers to Therapy, do they Exist in Hepatocellular Carcinoma
-
Wu, J. Predictive Biomarkers to Therapy, do they Exist in Hepatocellular Carcinoma. Chemotherapy, 2012, 1, e104.
-
(2012)
Chemotherapy
, vol.1
-
-
Wu, J.1
-
83
-
-
80053974116
-
Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma
-
Kaseb, A.O.; Morris, J.S.; Hassan, M.M.; Siddiqui, A.M.; Lin, E.; Xiao, L.; Abdalla, E.K.; Vauthey, J.N.; Aloia, T.A.; Krishnan, S. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J. Clin. Oncol., 2011, 29 (29), 3892-3899.
-
(2011)
J. Clin. Oncol
, vol.29
, Issue.29
, pp. 3892-3899
-
-
Kaseb, A.O.1
Morris, J.S.2
Hassan, M.M.3
Siddiqui, A.M.4
Lin, E.5
Xiao, L.6
Abdalla, E.K.7
Vauthey, J.N.8
Aloia, T.A.9
Krishnan, S.10
-
84
-
-
79960084386
-
Insulin-like growth factor-I and the liver
-
Bonefeld, K.; Møller, S. Insulin-like growth factor-I and the liver. Liver Int., 2011, 31 (7), 911-919.
-
(2011)
Liver Int
, vol.31
, Issue.7
, pp. 911-919
-
-
Bonefeld, K.1
Møller, S.2
-
85
-
-
0031934765
-
Role of growth factors in pancreatic cancer
-
Korc, M. Role of growth factors in pancreatic cancer. Surg. Oncol. Clin. N. Am., 1998, 7 (1), 25.
-
(1998)
Surg. Oncol. Clin. N. Am
, vol.7
, Issue.1
, pp. 25
-
-
Korc, M.1
-
86
-
-
0028997487
-
Insulin-like growth factor I overexpression in human pancreatic cancer: Evidence for autocrine and paracrine roles
-
Bergmann, U.; Funatomi, H.; Yokoyama, M.; Beger, H.G.; Korc, M. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res., 1995, 55 (10), 2007.
-
(2007)
Cancer Res
, vol.55
, Issue.10
, pp. 1995
-
-
Bergmann, U.1
Funatomi, H.2
Yokoyama, M.3
Beger, H.G.4
Korc, M.5
-
87
-
-
84858793843
-
Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer
-
Dong, X.; Li, Y.; Tang, H.; Chang, P.; Hess, K.R.; Abbruzzese, J.L.; Li, D. Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer. Cancer Epidemiol., 2012, 36 (2), 206-211.
-
(2012)
Cancer Epidemiol
, vol.36
, Issue.2
, pp. 206-211
-
-
Dong, X.1
Li, Y.2
Tang, H.3
Chang, P.4
Hess, K.R.5
Abbruzzese, J.L.6
Li, D.7
-
88
-
-
79954614279
-
Targeting the insulin-like growth factor network in cancer therapy
-
Heidegger, I.; Pircher, A.; Klocker, H.; Massoner, P. Targeting the insulin-like growth factor network in cancer therapy. Cancer Biol. Ther., 2011, 11 (8), 701-707.
-
(2011)
Cancer Biol. Ther
, vol.11
, Issue.8
, pp. 701-707
-
-
Heidegger, I.1
Pircher, A.2
Klocker, H.3
Massoner, P.4
-
89
-
-
79951860072
-
Small is beautiful: Insulin-like growth factors and their role in growth, development, and cancer
-
Maki, R.G. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J. Clin. Oncol., 2010, 28 (33), 4985-4995.
-
(2010)
J. Clin. Oncol
, vol.28
, Issue.33
, pp. 4985-4995
-
-
Maki, R.G.1
-
90
-
-
79960284689
-
Levels of insulin-like growth factor during pregnancy and maternal cancer risk: A nested case-control study
-
Jeffreys, M.; Northstone, K.; Holly, J.; Emmett, P.; Gunnell, D. Levels of insulin-like growth factor during pregnancy and maternal cancer risk: a nested case-control study. Cancer Causes Control, 2011, 22 (7), 945-953.
-
(2011)
Cancer Causes Control
, vol.22
, Issue.7
, pp. 945-953
-
-
Jeffreys, M.1
Northstone, K.2
Holly, J.3
Emmett, P.4
Gunnell, D.5
-
91
-
-
84855885822
-
Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy
-
Tognon, C.E.; Sorensen, P.H.B. Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy. Expert Opin. Ther. Targets, 2012, 16 (1), 33-48.
-
(2012)
Expert Opin. Ther. Targets
, vol.16
, Issue.1
, pp. 33-48
-
-
Tognon, C.E.1
Sorensen, P.H.B.2
-
92
-
-
55849095485
-
Role of ubiquitination in IGF-1 receptor signaling and degradation
-
Sehat, B.; Andersson, S.; Vasilcanu, R.; Girnita, L.; Larsson, O. Role of ubiquitination in IGF-1 receptor signaling and degradation. PLoS ONE, 2007, 2 (4), e340.
-
(2007)
PLoS ONE
, vol.2
, Issue.4
-
-
Sehat, B.1
Andersson, S.2
Vasilcanu, R.3
Girnita, L.4
Larsson, O.5
-
93
-
-
0026660653
-
Phosphatidylinositol 3'-kinase is activated by association with IRS-1 during insulin stimulation
-
Backer, J.M.; Myers Jr, M.G.; Shoelson, S.E.; Chin, D.J.; Sun, X.; Miralpeix, M.; Hu, P.; Margolis, B.; Skolnik, E.; Schlessinger, J. Phosphatidylinositol 3'-kinase is activated by association with IRS-1 during insulin stimulation. EMBO J., 1992, 11 (9), 3469.
-
(1992)
EMBO J
, vol.11
, Issue.9
, pp. 3469
-
-
Backer, J.M.1
Myers, M.G.2
Shoelson, S.E.3
Chin, D.J.4
Sun, X.5
Miralpeix, M.6
Hu, P.7
Margolis, B.8
Skolnik, E.9
Schlessinger, J.10
-
94
-
-
0031743951
-
Insulin-like growth factor-I receptor signal transduction: At the interface between physiology and cell biology
-
Butler, A.A.; Yakar, S.; Gewolb, I.H.; Karas, M.; Okubo, Y.; LeRoith, D. Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology. Comp. Biochem. Physiol., Part B: Biochem. Mol. Biol., 1998, 121 (1), 19-26.
-
(1998)
Comp. Biochem. Physiol., Part B: Biochem. Mol. Biol
, vol.121
, Issue.1
, pp. 19-26
-
-
Butler, A.A.1
Yakar, S.2
Gewolb, I.H.3
Karas, M.4
Okubo, Y.5
Leroith, D.6
-
95
-
-
0031918624
-
The IRS-signalling system: A network of docking proteins that mediate insulin action
-
White, M.F. The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol. Cell. Biochem., 1998, 182 (1), 3-11.
-
(1998)
Mol. Cell. Biochem
, vol.182
, Issue.1
, pp. 3-11
-
-
White, M.F.1
-
96
-
-
0027312272
-
Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling
-
Li, N.; Batzer, A.; Daly, R.; Yajnik, V.; Skolnik, E.; Chardin, P.; Bar-Sagi, D.; Margolis, B.; Schlessinger, J. Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature, 1993, 363 (6424), 85-88.
-
(1993)
Nature
, vol.363
, Issue.6424
, pp. 85-88
-
-
Li, N.1
Batzer, A.2
Daly, R.3
Yajnik, V.4
Skolnik, E.5
Chardin, P.6
Bar-Sagi, D.7
Margolis, B.8
Schlessinger, J.9
-
97
-
-
0028123457
-
A new function for a phosphotyrosine phosphatase: Linking GRB2-Sos to a receptor tyrosine kinase
-
Li, W.; Nishimura, R.; Kashishian, A.; Batzer, A.G.; Kim, W.; Cooper, J.A.; Schlessinger, J. A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase. Mol. Cell. Biol., 1994, 14 (1), 509-517.
-
(1994)
Mol. Cell. Biol
, vol.14
, Issue.1
, pp. 509-517
-
-
Li, W.1
Nishimura, R.2
Kashishian, A.3
Batzer, A.G.4
Kim, W.5
Cooper, J.A.6
Schlessinger, J.7
-
98
-
-
0029763774
-
Hydrogen peroxide induces complex formation of SHC-Grb2-SOS with receptor tyrosine kinase and activates Ras and extracellular signal-regulated protein kinases group of mitogen-activated protein kinases
-
Rao, G.N. Hydrogen peroxide induces complex formation of SHC-Grb2-SOS with receptor tyrosine kinase and activates Ras and extracellular signal-regulated protein kinases group of mitogen-activated protein kinases. Oncogene, 1996, 13 (4), 713.
-
(1996)
Oncogene
, vol.13
, Issue.4
, pp. 713
-
-
Rao, G.N.1
-
99
-
-
0027250250
-
Mammalian Ras interacts directly with the serine/threonine kinase Raf
-
Vojtek, A.B.; Hollenberg, S.M.; Cooper, J.A. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell, 1993, 74 (1), 205-214.
-
(1993)
Cell
, vol.74
, Issue.1
, pp. 205-214
-
-
Vojtek, A.B.1
Hollenberg, S.M.2
Cooper, J.A.3
-
100
-
-
0034667593
-
Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
-
Kolch, W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem. J., 2000, 351 (Pt 2), 289.
-
(2000)
Biochem. J
, vol.351
, Issue.Pt 2
, pp. 289
-
-
Kolch, W.1
-
101
-
-
0027337519
-
Complexes of Ras. GTP with Raf-1 and mitogen-activated protein kinase kinase
-
Moodie, S.A.; Willumsen, B.M.; Weber, M.J.; Wolfman, A. Complexes of Ras. GTP with Raf-1 and mitogen-activated protein kinase kinase. Science, 1993, 260 (5114), 1658-1661.
-
(1993)
Science
, vol.260
, Issue.5114
, pp. 1658-1661
-
-
Moodie, S.A.1
Willumsen, B.M.2
Weber, M.J.3
Wolfman, A.4
-
102
-
-
33746565515
-
Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway
-
Gollob, J.A.; Wilhelm, S.; Carter, C.; Kelley, S.L. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin. Oncol., 2006, 33 (4), 392-406.
-
(2006)
Semin. Oncol
, vol.33
, Issue.4
, pp. 392-406
-
-
Gollob, J.A.1
Wilhelm, S.2
Carter, C.3
Kelley, S.L.4
-
103
-
-
0027215820
-
A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf
-
Lange-Carter, C.A.; Pleiman, C.M.; Gardner, A.M.; Blumer, K.J.; Johnson, G.L. A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. Science, 1993, 260 (5106), 315-319.
-
(1993)
Science
, vol.260
, Issue.5106
, pp. 315-319
-
-
Lange-Carter, C.A.1
Pleiman, C.M.2
Gardner, A.M.3
Blumer, K.J.4
Johnson, G.L.5
-
104
-
-
10944260245
-
Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1
-
Mawson, A.; Lai, A.; Carroll, J.S.; Sergio, C.M.; Mitchell, C.J.; Sarcevic, B. Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. Mol. Cell. Endocrinol., 2005, 229 (1-2), 161-173.
-
(2005)
Mol. Cell. Endocrinol
, vol.229
, Issue.1-2
, pp. 161-173
-
-
Mawson, A.1
Lai, A.2
Carroll, J.S.3
Sergio, C.M.4
Mitchell, C.J.5
Sarcevic, B.6
-
105
-
-
84877798991
-
Taghavi, P
-
Goode, J.A.; Chadwick, D.J., Ed.; John wiley & Sons, West Sussex
-
Semenza, G.L.; Artemov, D.; Bedi, A.; Bhujwalla, Z.; Chiles, K.; Feldser, D.; Laughner, E.; Ravi, R.; Simons, J.; Taghavi, P. In: The Tumour Microenvironment: Causes and Consequences of Hypoxia and Acidity; Goode, J.A.; Chadwick, D.J., Ed.; John wiley & Sons, West Sussex, 2001, pp. 251-264.
-
(2001)
The Tumour Microenvironment: Causes and Consequences of Hypoxia and Acidity
, pp. 251-264
-
-
Semenza, G.L.1
Artemov, D.2
Bedi, A.3
Bhujwalla, Z.4
Chiles, K.5
Feldser, D.6
Laughner, E.7
Ravi, R.8
Simons, J.9
-
106
-
-
33745886839
-
Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21 WAF1/CIP1
-
Chen, C.; Chang, Y.C.; Liu, C.L.; Chang, K.J.; Guo, I.C. Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21 WAF1/CIP1. Breast Cancer Res. Treat., 2006, 98 (2), 121-132.
-
(2006)
Breast Cancer Res. Treat
, vol.98
, Issue.2
, pp. 121-132
-
-
Chen, C.1
Chang, Y.C.2
Liu, C.L.3
Chang, K.J.4
Guo, I.C.5
-
107
-
-
21244471120
-
Sustained Akt/PKB activation and transient attenuation of c-jun N-terminal kinase in the inhibition of apoptosis by IGF-1 in vascular smooth muscle cells
-
Allen, R.; Krueger, K.; Dhume, A.; Agrawal, D. Sustained Akt/PKB activation and transient attenuation of c-jun N-terminal kinase in the inhibition of apoptosis by IGF-1 in vascular smooth muscle cells. Apoptosis, 2005, 10 (3), 525-535.
-
(2005)
Apoptosis
, vol.10
, Issue.3
, pp. 525-535
-
-
Allen, R.1
Krueger, K.2
Dhume, A.3
Agrawal, D.4
-
108
-
-
34247369371
-
ETS transcription factors in endocrine systems
-
Gutierrez-Hartmann, A.; Duval, D.L.; Bradford, A.P. ETS transcription factors in endocrine systems. Trends Endocrinol. Metab., 2007, 18 (4), 150-158.
-
(2007)
Trends Endocrinol. Metab
, vol.18
, Issue.4
, pp. 150-158
-
-
Gutierrez-Hartmann, A.1
Duval, D.L.2
Bradford, A.P.3
-
109
-
-
0037098951
-
PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway
-
Weng, L.P.; Brown, J.L.; Baker, K.M.; Ostrowski, M.C.; Eng, C. PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway. Hum. Mol. Genet., 2002, 11 (15), 1687-1696.
-
(2002)
Hum. Mol. Genet
, vol.11
, Issue.15
, pp. 1687-1696
-
-
Weng, L.P.1
Brown, J.L.2
Baker, K.M.3
Ostrowski, M.C.4
Eng, C.5
-
110
-
-
0033035897
-
ERK Pathway Mediates the Activation of Cdk2 in IGF-1-Induced Proliferation of Human Osteosarcoma MG-63 Cells
-
Zhang, W.; Lee, J.C.; Kumar, S.; Gowen, M. ERK Pathway Mediates the Activation of Cdk2 in IGF-1-Induced Proliferation of Human Osteosarcoma MG-63 Cells. J. Bone Miner. Res., 1999, 14 (4), 528-535.
-
(1999)
J. Bone Miner. Res
, vol.14
, Issue.4
, pp. 528-535
-
-
Zhang, W.1
Lee, J.C.2
Kumar, S.3
Gowen, M.4
-
111
-
-
0033614021
-
Insulin-like growth factor I-mediated activation of the transcription factor cAMP response element-binding protein in PC12 cells
-
Pugazhenthi, S.; Boras, T.; O'Connor, D.; Meintzer, M.K.; Heidenreich, K.A.; Reusch, J.E.B. Insulin-like growth factor I-mediated activation of the transcription factor cAMP response element-binding protein in PC12 cells. J. Biol. Chem., 1999, 274 (5), 2829-2837.
-
(1999)
J. Biol. Chem
, vol.274
, Issue.5
, pp. 2829-2837
-
-
Pugazhenthi, S.1
Boras, T.2
O'Connor, D.3
Meintzer, M.K.4
Heidenreich, K.A.5
Reusch, J.E.B.6
-
112
-
-
0036669037
-
Control of cell survival by IGF signaling pathways
-
Vincent, A.M.; Feldman, E.L. Control of cell survival by IGF signaling pathways. Growth Horm. IGF Res., 2002, 12 (4), 193-197.
-
(2002)
Growth Horm. IGF Res
, vol.12
, Issue.4
, pp. 193-197
-
-
Vincent, A.M.1
Feldman, E.L.2
-
113
-
-
0035940387
-
In cardiomyocyte hypoxia, insulin-like growth factor-I-induced antiapoptotic signaling requires phosphatidylinositol-3-OH-kinase-dependent and mitogen-activated protein kinase-dependent activation of the transcription factor cAMP response element-binding protein
-
Mehrhof, F.B.; Müller, F.U.; Bergmann, M.W.; Li, P.; Wang, Y.; Schmitz, W.; Dietz, R.; von Harsdorf, R. In cardiomyocyte hypoxia, insulin-like growth factor-I-induced antiapoptotic signaling requires phosphatidylinositol-3-OH-kinase-dependent and mitogen-activated protein kinase-dependent activation of the transcription factor cAMP response element-binding protein. Circulation, 2001, 104 (17), 2088-2094.
-
(2001)
Circulation
, vol.104
, Issue.17
, pp. 2088-2094
-
-
Mehrhof, F.B.1
Müller, F.U.2
Bergmann, M.W.3
Li, P.4
Wang, Y.5
Schmitz, W.6
Dietz, R.7
von Harsdorf, R.8
-
114
-
-
57049094383
-
Activation of adenosine A1 receptor-induced neural stem cell proliferation via MEK/ERK and Akt signaling pathways
-
Migita, H.; Kominami, K.; Higashida, M.; Maruyama, R.; Tuchida, N.; McDonald, F.; Shimada, F.; Sakurada, K. Activation of adenosine A1 receptor-induced neural stem cell proliferation via MEK/ERK and Akt signaling pathways. J. Neurosci. Res., 2008, 86 (13), 2820-2828.
-
(2008)
J. Neurosci. Res
, vol.86
, Issue.13
, pp. 2820-2828
-
-
Migita, H.1
Kominami, K.2
Higashida, M.3
Maruyama, R.4
Tuchida, N.5
McDonald, F.6
Shimada, F.7
Sakurada, K.8
-
115
-
-
34547817154
-
A new paradigm for protein kinase inhibition: Blocking phosphorylation without directly targeting ATP binding
-
Bogoyevitch, M.A.; Fairlie, D.P. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov. Today, 2007, 12 (15-16), 622-633.
-
(2007)
Drug Discov. Today
, vol.12
, Issue.15-16
, pp. 622-633
-
-
Bogoyevitch, M.A.1
Fairlie, D.P.2
-
116
-
-
33749319933
-
Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells
-
Lee, H.C.; Tian, B.; Sedivy, J.M.; Wands, J.R.; Kim, M. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology, 2006, 131 (4), 1208-1217.
-
(2006)
Gastroenterology
, vol.131
, Issue.4
, pp. 1208-1217
-
-
Lee, H.C.1
Tian, B.2
Sedivy, J.M.3
Wands, J.R.4
Kim, M.5
-
118
-
-
0034954277
-
X protein of hepatitis B virus modulates cytokine and growth factor related signal transduction pathways during the course of viral infections and hepatocarcinogenesis
-
Diao, J.; Garces, R.; Richardson, C.D. X protein of hepatitis B virus modulates cytokine and growth factor related signal transduction pathways during the course of viral infections and hepatocarcinogenesis. Cytokine Growth Factor Rev., 2001, 12 (2), 189-205.
-
(2001)
Cytokine Growth Factor Rev
, vol.12
, Issue.2
, pp. 189-205
-
-
Diao, J.1
Garces, R.2
Richardson, C.D.3
-
119
-
-
3843138659
-
B-Raf and insulin synergistically prevent apoptosis and induce cell cycle progression in hematopoietic cells
-
Shelton, J.G.; Chang, F.; Lee, J.T.; Franklin, R.A.; Steelman, L.S.; McCubrey, J.A. B-Raf and insulin synergistically prevent apoptosis and induce cell cycle progression in hematopoietic cells. Cell cycle, 2004, 3 (2), 189-196.
-
(2004)
Cell Cycle
, vol.3
, Issue.2
, pp. 189-196
-
-
Shelton, J.G.1
Chang, F.2
Lee, J.T.3
Franklin, R.A.4
Steelman, L.S.5
McCubrey, J.A.6
-
120
-
-
0037810249
-
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: Potential targeting for therapeutic intervention
-
Chang, F.; Steelman, L.; Lee, J.; Shelton, J.; Navolanic, P.; Blalock, W.; Franklin, R.; McCubrey, J. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia, 2003, 17 (7), 1263-1293.
-
(2003)
Leukemia
, vol.17
, Issue.7
, pp. 1263-1293
-
-
Chang, F.1
Steelman, L.2
Lee, J.3
Shelton, J.4
Navolanic, P.5
Blalock, W.6
Franklin, R.7
McCubrey, J.8
-
121
-
-
0029808748
-
Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways
-
Whitmarsh, A.; Davis, R. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med., 1996, 74 (10), 589-607.
-
(1996)
J. Mol. Med
, vol.74
, Issue.10
, pp. 589-607
-
-
Whitmarsh, A.1
Davis, R.2
-
122
-
-
0347997608
-
MAPK signal pathways in the regulation of cell proliferation in mammalian cells
-
Zhang, W.; Liu, H.T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res., 2002, 12 (1), 9-18.
-
(2002)
Cell Res
, vol.12
, Issue.1
, pp. 9-18
-
-
Zhang, W.1
Liu, H.T.2
-
123
-
-
34248572839
-
MAP kinases and the control of nuclear events
-
Turjanski, A.; Vaque, J.; Gutkind, J. MAP kinases and the control of nuclear events. Oncogene, 2007, 26 (22), 3240-3253.
-
(2007)
Oncogene
, vol.26
, Issue.22
, pp. 3240-3253
-
-
Turjanski, A.1
Vaque, J.2
Gutkind, J.3
-
124
-
-
0036187036
-
Three-dimensional structure of the apoptosome: Implications for assembly, procaspase-9 binding, and activation
-
Acehan, D.; Jiang, X.; Morgan, D.G.; Heuser, J.E.; Wang, X.; Akey, C.W. Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol. Cell, 2002, 9 (2), 423-432.
-
(2002)
Mol. Cell
, vol.9
, Issue.2
, pp. 423-432
-
-
Acehan, D.1
Jiang, X.2
Morgan, D.G.3
Heuser, J.E.4
Wang, X.5
Akey, C.W.6
-
125
-
-
0035798361
-
Crystal structure of a procaspase-7 zymogen: Mechanisms of activation and substrate binding
-
Chai, J.; Wu, Q.; Shiozaki, E.; Srinivasula, S.M.; Alnemri, E.S.; Shi, Y. Crystal structure of a procaspase-7 zymogen: mechanisms of activation and substrate binding. Cell, 2001, 107 (3), 399-407.
-
(2001)
Cell
, vol.107
, Issue.3
, pp. 399-407
-
-
Chai, J.1
Wu, Q.2
Shiozaki, E.3
Srinivasula, S.M.4
Alnemri, E.S.5
Shi, Y.6
-
126
-
-
0033605722
-
Caspase-9 can be activated without proteolytic processing
-
Stennicke, H.R.; Deveraux, Q.L.; Humke, E.W.; Reed, J.C.; Dixit, V.M.; Salvesen, G.S. Caspase-9 can be activated without proteolytic processing. Sci. STKE, 1999, 274 (13), 8359.
-
(1999)
Sci. STKE
, vol.274
, Issue.13
, pp. 8359
-
-
Stennicke, H.R.1
Deveraux, Q.L.2
Humke, E.W.3
Reed, J.C.4
Dixit, V.M.5
Salvesen, G.S.6
-
127
-
-
0035909889
-
Structural basis for the activation of human procaspase-7
-
Riedl, S.J.; Fuentes-Prior, P.; Renatus, M.; Kairies, N.; Krapp, S.; Huber, R.; Salvesen, G.S.; Bode, W. Structural basis for the activation of human procaspase-7. PNAS, 2001, 98 (26), 14790.
-
(2001)
PNAS
, vol.98
, Issue.26
, pp. 14790
-
-
Riedl, S.J.1
Fuentes-Prior, P.2
Renatus, M.3
Kairies, N.4
Krapp, S.5
Huber, R.6
Salvesen, G.S.7
Bode, W.8
-
128
-
-
0037058964
-
Structure and zymogen activation of caspases
-
Donepudi, M.; Grütter, M.G. Structure and zymogen activation of caspases. Biophys. Chem., 2002, 101, 145-153.
-
(2002)
Biophys. Chem
, vol.101
, pp. 145-153
-
-
Donepudi, M.1
Grütter, M.G.2
-
129
-
-
0038726089
-
Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK
-
Allan, L.A.; Morrice, N.; Brady, S.; Magee, G.; Pathak, S.; Clarke, P.R. Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat. Cell Biol., 2003, 5 (7), 647-654.
-
(2003)
Nat. Cell Biol
, vol.5
, Issue.7
, pp. 647-654
-
-
Allan, L.A.1
Morrice, N.2
Brady, S.3
Magee, G.4
Pathak, S.5
Clarke, P.R.6
-
130
-
-
0037806885
-
Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review)
-
Chang, F.; Steelman, L.S.; Shelton, J.G.; Lee, J.T.; Navolanic, P.M.; Blalock, W.L.; Franklin, R.; McCubrey, J.A. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int. J. Oncol., 2003, 22 (3), 469.
-
(2003)
Int. J. Oncol
, vol.22
, Issue.3
, pp. 469
-
-
Chang, F.1
Steelman, L.S.2
Shelton, J.G.3
Lee, J.T.4
Navolanic, P.M.5
Blalock, W.L.6
Franklin, R.7
McCubrey, J.A.8
-
131
-
-
33947594129
-
Hyperactive Ras in developmental disorders and cancer
-
Schubbert, S.; Shannon, K.; Bollag, G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer, 2007, 7 (4), 295-308.
-
(2007)
Nat. Rev. Cancer
, vol.7
, Issue.4
, pp. 295-308
-
-
Schubbert, S.1
Shannon, K.2
Bollag, G.3
-
132
-
-
32044466838
-
Exploiting the PI3K/AKT pathway for cancer drug discovery
-
Hennessy, B.T.; Smith, D.L.; Ram, P.T.; Lu, Y.; Mills, G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov., 2005, 4 (12), 988-1004.
-
(2005)
Nat. Rev. Drug Discov
, vol.4
, Issue.12
, pp. 988-1004
-
-
Hennessy, B.T.1
Smith, D.L.2
Ram, P.T.3
Lu, Y.4
Mills, G.B.5
-
133
-
-
13844273087
-
PI3K-Akt pathway: Its functions and alterations in human cancer
-
Osaki, M.; Oshimura, M.; Ito, H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis, 2004, 9 (6), 667-676.
-
(2004)
Apoptosis
, vol.9
, Issue.6
, pp. 667-676
-
-
Osaki, M.1
Oshimura, M.2
Ito, H.3
-
134
-
-
0031887249
-
Regulation of the p85/p110 phosphatidylinositol 3'-kinase: Stabilization and inhibition of the p110α catalytic subunit by the p85 regulatory subunit
-
Yu, J.; Zhang, Y.; McIlroy, J.; Rordorf-Nikolic, T.; Orr, G.A.; Backer, J.M. Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110α catalytic subunit by the p85 regulatory subunit. Mol. Cell. Biol., 1998, 18 (3), 1379-1387.
-
(1998)
Mol. Cell. Biol
, vol.18
, Issue.3
, pp. 1379-1387
-
-
Yu, J.1
Zhang, Y.2
McIlroy, J.3
Rordorf-Nikolic, T.4
Orr, G.A.5
Backer, J.M.6
-
135
-
-
0036632368
-
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
-
Vivanco, I.; Sawyers, C.L. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat. Rev. Cancer, 2002, 2 (7), 489-501.
-
(2002)
Nat. Rev. Cancer
, vol.2
, Issue.7
, pp. 489-501
-
-
Vivanco, I.1
Sawyers, C.L.2
-
136
-
-
0027191192
-
Solution structure and ligand-binding site of the SH3 domain of the p85 alpha subunit of phosphatidylinositol 3-kinase
-
Booker, G.W.; Gout, I.; Downing, A.; Driscoll, P.C.; Boyd, J.; Waterfield, M.D.; Campbell, I.D. Solution structure and ligand-binding site of the SH3 domain of the p85 alpha subunit of phosphatidylinositol 3-kinase. Cell, 1993, 73 (4), 813.
-
(1993)
Cell
, vol.73
, Issue.4
, pp. 813
-
-
Booker, G.W.1
Gout, I.2
Downing, A.3
Driscoll, P.C.4
Boyd, J.5
Waterfield, M.D.6
Campbell, I.D.7
-
137
-
-
0028120902
-
Phosphatidylinositol 3-kinase activation is mediated by high-affinity interactions between distinct domains within the p110 and p85 subunits
-
Holt, K.H.; Olson, L.; Moye-Rowley, W.S.; Pessin, J.E. Phosphatidylinositol 3-kinase activation is mediated by high-affinity interactions between distinct domains within the p110 and p85 subunits. Mol. Cell. Biol., 1994, 14 (1), 42-49.
-
(1994)
Mol. Cell. Biol
, vol.14
, Issue.1
, pp. 42-49
-
-
Holt, K.H.1
Olson, L.2
Moye-Rowley, W.S.3
Pessin, J.E.4
-
138
-
-
0033952239
-
The PI 3-kinase isoforms p110 (alpha) and p110 (beta) have differential roles in PDGF-and insulin-mediated signaling
-
Hooshmand-Rad, R.; Hájková, L.; Klint, P.; Karlsson, R.; Vanhaesebroeck, B.; Claesson-Welsh, L.; Heldin, C.H. The PI 3-kinase isoforms p110 (alpha) and p110 (beta) have differential roles in PDGF-and insulin-mediated signaling. J. Cell Sci., 2000, 113 (2), 207-214.
-
(2000)
J. Cell Sci
, vol.113
, Issue.2
, pp. 207-214
-
-
Hooshmand-Rad, R.1
Hájková, L.2
Klint, P.3
Karlsson, R.4
Vanhaesebroeck, B.5
Claesson-Welsh, L.6
Heldin, C.H.7
-
139
-
-
0034653608
-
The PI3K-PDK1 connection: More than just a road to PKB
-
Vanhaesebroeck, B.; Alessi, D.R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J., 2000, 346 (Pt 3), 561.
-
(2000)
Biochem. J
, vol.346
, Issue.Pt 3
, pp. 561
-
-
Vanhaesebroeck, B.1
Alessi, D.R.2
-
140
-
-
0035020950
-
Phosphoinositide 3-kinase signalling pathways
-
Cantrell, D.A. Phosphoinositide 3-kinase signalling pathways. J. Cell Sci., 2001, 114 (8), 1439-1445.
-
(2001)
J. Cell Sci
, vol.114
, Issue.8
, pp. 1439-1445
-
-
Cantrell, D.A.1
-
141
-
-
0032443803
-
The akt kinase: Molecular determinants of oncogenicity
-
Aoki, M.; Batista, O.; Bellacosa, A.; Tsichlis, P.; Vogt, P.K. The akt kinase: molecular determinants of oncogenicity. PNAS, 1998, 95 (25), 14950.
-
(1998)
PNAS
, vol.95
, Issue.25
, pp. 14950
-
-
Aoki, M.1
Batista, O.2
Bellacosa, A.3
Tsichlis, P.4
Vogt, P.K.5
-
142
-
-
0032053709
-
Mechanisms and consequences of activation of protein kinase B/Akt
-
Downward, J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol., 1998, 10 (2), 262-267.
-
(1998)
Curr. Opin. Cell Biol
, vol.10
, Issue.2
, pp. 262-267
-
-
Downward, J.1
-
143
-
-
0033604585
-
The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB
-
Kandel, E.S.; Hay, N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp. Cell Res., 1999, 253 (1), 210-229.
-
(1999)
Exp. Cell Res
, vol.253
, Issue.1
, pp. 210-229
-
-
Kandel, E.S.1
Hay, N.2
-
144
-
-
10744228945
-
Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-xL pathway
-
Sekharam, M.; Zhao, H.; Sun, M.; Fang, Q.; Zhang, Q.; Yuan, Z.; Dan, H.C.; Boulware, D.; Cheng, J.Q.; Coppola, D. Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-xL pathway. Cancer Res., 2003, 63 (22), 7708.
-
(2003)
Cancer Res
, vol.63
, Issue.22
, pp. 7708
-
-
Sekharam, M.1
Zhao, H.2
Sun, M.3
Fang, Q.4
Zhang, Q.5
Yuan, Z.6
Dan, H.C.7
Boulware, D.8
Cheng, J.Q.9
Coppola, D.10
-
145
-
-
0035853833
-
Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology
-
Plas, D.R.; Talapatra, S.; Edinger, A.L.; Rathmell, J.C.; Thompson, C.B. Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology. J. Biol. Chem., 2001, 276 (15), 12041-12048.
-
(2001)
J. Biol. Chem
, vol.276
, Issue.15
, pp. 12041-12048
-
-
Plas, D.R.1
Talapatra, S.2
Edinger, A.L.3
Rathmell, J.C.4
Thompson, C.B.5
-
146
-
-
0030702123
-
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
-
Datta, S.R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 1997, 91 (2), 231-242.
-
(1997)
Cell
, vol.91
, Issue.2
, pp. 231-242
-
-
Datta, S.R.1
Dudek, H.2
Tao, X.3
Masters, S.4
Fu, H.5
Gotoh, Y.6
Greenberg, M.E.7
-
147
-
-
0033635235
-
14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation
-
Datta, S.R.; Katsov, A.; Hu, L.; Petros, A.; Fesik, S.W.; Yaffe, M.B.; Greenberg, M.E. 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol. Cell, 2000, 6 (1), 41-51.
-
(2000)
Mol. Cell
, vol.6
, Issue.1
, pp. 41-51
-
-
Datta, S.R.1
Katsov, A.2
Hu, L.3
Petros, A.4
Fesik, S.W.5
Yaffe, M.B.6
Greenberg, M.E.7
-
148
-
-
0034682812
-
BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival
-
Tan, Y.; Demeter, M.R.; Ruan, H.; Comb, M.J. BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival. J. Biol. Chem., 2000, 275 (33), 25865-25869.
-
(2000)
J. Biol. Chem
, vol.275
, Issue.33
, pp. 25865-25869
-
-
Tan, Y.1
Demeter, M.R.2
Ruan, H.3
Comb, M.J.4
-
149
-
-
0035843148
-
Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation
-
Desbois-Mouthon, C.; Cadoret, A.; Blivet-Van Eggelpoël, M.J.; Bertrand, F.; Cherqui, G.; Perret, C.; Capeau, J. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene, 2001, 20 (2), 252.
-
(2001)
Oncogene
, vol.20
, Issue.2
, pp. 252
-
-
Desbois-Mouthon, C.1
Cadoret, A.2
Blivet-Van Eggelpoël, M.J.3
Bertrand, F.4
Cherqui, G.5
Perret, C.6
Capeau, J.7
-
150
-
-
0037383322
-
GSK-3: Tricks of the trade for a multi-tasking kinase
-
Doble, B.W.; Woodgett, J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci., 2003, 116 (7), 1175-1186.
-
(2003)
J. Cell Sci
, vol.116
, Issue.7
, pp. 1175-1186
-
-
Doble, B.W.1
Woodgett, J.R.2
-
151
-
-
24944480788
-
The Akt-mTOR tango and its relevance to cancer
-
Hay, N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell, 2005, 8 (3), 179-183.
-
(2005)
Cancer Cell
, vol.8
, Issue.3
, pp. 179-183
-
-
Hay, N.1
-
152
-
-
0347988005
-
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR
-
Zhang, H.; Cicchetti, G.; Onda, H.; Koon, H.B.; Asrican, K.; Bajraszewski, N.; Vazquez, F.; Carpenter, C.L.; Kwiatkowski, D.J. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Invest., 2003, 112 (8), 1223-1233.
-
(2003)
J. Clin. Invest
, vol.112
, Issue.8
, pp. 1223-1233
-
-
Zhang, H.1
Cicchetti, G.2
Onda, H.3
Koon, H.B.4
Asrican, K.5
Bajraszewski, N.6
Vazquez, F.7
Carpenter, C.L.8
Kwiatkowski, D.J.9
-
153
-
-
0036713778
-
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
-
Inoki, K.; Li, Y.; Zhu, T.; Wu, J.; Guan, K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol., 2002, 4 (9), 648-657.
-
(2002)
Nat. Cell Biol
, vol.4
, Issue.9
, pp. 648-657
-
-
Inoki, K.1
Li, Y.2
Zhu, T.3
Wu, J.4
Guan, K.L.5
-
154
-
-
36049043184
-
Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38
-
Bai, X.; Ma, D.; Liu, A.; Shen, X.; Wang, Q.J.; Liu, Y.; Jiang, Y. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Sci. STKE, 2007, 318 (5852), 977.
-
(2007)
Sci. STKE
, vol.318
, Issue.5852
, pp. 977
-
-
Bai, X.1
Ma, D.2
Liu, A.3
Shen, X.4
Wang, Q.J.5
Liu, Y.6
Jiang, Y.7
-
155
-
-
84875226458
-
MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor
-
Zhao, X.; Dou, W.; He, L.; Liang, S.; Tie, J.; Liu, C.; Li, T.; Lu, Y.; Mo, P.; Shi, Y. MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. Oncogene, 2012.
-
(2012)
Oncogene
-
-
Zhao, X.1
Dou, W.2
He, L.3
Liang, S.4
Tie, J.5
Liu, C.6
Li, T.7
Lu, Y.8
Mo, P.9
Shi, Y.10
-
156
-
-
84861991534
-
MiR-139 Inhibits Invasion and Metastasis of Colorectal Cancer by Targeting the Type I Insulin-like Growth Factor Receptor
-
Shen, K.; Liang, Q.; Xu, K.; Cui, D.; Jiang, L.; Yin, P.; Lu, Y.; Li, Q.; Liu, J. MiR-139 Inhibits Invasion and Metastasis of Colorectal Cancer by Targeting the Type I Insulin-like Growth Factor Receptor. Biochem. Pharmacol., 2012, 84 (3), 320-330.
-
(2012)
Biochem. Pharmacol
, vol.84
, Issue.3
, pp. 320-330
-
-
Shen, K.1
Liang, Q.2
Xu, K.3
Cui, D.4
Jiang, L.5
Yin, P.6
Lu, Y.7
Li, Q.8
Liu, J.9
-
157
-
-
84876134466
-
MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer
-
Guo, S.; Jiang, C.; Wang, G.; Li, Y.; Wang, C.; Guo, X.; Yang, R.; Feng, Y.; Wang, F.; Tseng, H. MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene, 2012.
-
(2012)
Oncogene
-
-
Guo, S.1
Jiang, C.2
Wang, G.3
Li, Y.4
Wang, C.5
Guo, X.6
Yang, R.7
Feng, Y.8
Wang, F.9
Tseng, H.10
-
158
-
-
3042775027
-
The insulin like growth factor-1 receptor (IGF-1R) as a drug target: Novel approaches to cancer therapy
-
Bähr, C.; Groner, B. The insulin like growth factor-1 receptor (IGF-1R) as a drug target: novel approaches to cancer therapy. Growth Horm. IGF Res., 2004, 14 (4), 287-295.
-
(2004)
Growth Horm. IGF Res
, vol.14
, Issue.4
, pp. 287-295
-
-
Bähr, C.1
Groner, B.2
-
159
-
-
0242624594
-
Growth factor receptors as therapeutic targets: Strategies to inhibit the insulin-like growth factor I receptor
-
Surmacz, E. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene, 2003, 22 (42), 6589-6597.
-
(2003)
Oncogene
, vol.22
, Issue.42
, pp. 6589-6597
-
-
Surmacz, E.1
-
160
-
-
0034719133
-
Substrate competitive inhibitors of IGF-1 receptor kinase
-
Blum, G.; Gazit, A.; Levitzki, A. Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry (Mosc). 2000, 39 (51), 15705-15712.
-
(2000)
Biochemistry (Mosc)
, vol.39
, Issue.51
, pp. 15705-15712
-
-
Blum, G.1
Gazit, A.2
Levitzki, A.3
-
161
-
-
75249097799
-
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: A phase 1 expansion cohort study
-
Olmos, D.; Postel-Vinay, S.; Molife, L.; Okuno, S.H.; Schuetze, S.M.; Paccagnella, M.L.; Batzel, G.N.; Yin, D.; Pritchard-Jones, K.; Judson, I. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol., 2010, 11 (2), 129-135.
-
(2010)
Lancet Oncol
, vol.11
, Issue.2
, pp. 129-135
-
-
Olmos, D.1
Postel-Vinay, S.2
Molife, L.3
Okuno, S.H.4
Schuetze, S.M.5
Paccagnella, M.L.6
Batzel, G.N.7
Yin, D.8
Pritchard-Jones, K.9
Judson, I.10
-
162
-
-
70350218696
-
High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507)
-
Gong, Y.; Yao, E.; Shen, R.; Goel, A.; Arcila, M.; Teruya-Feldstein, J.; Zakowski, M.F.; Frankel, S.; Peifer, M.; Thomas, R.K. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS ONE, 2009, 4 (10), e7273.
-
(2009)
PLoS ONE
, vol.4
, Issue.10
-
-
Gong, Y.1
Yao, E.2
Shen, R.3
Goel, A.4
Arcila, M.5
Teruya-Feldstein, J.6
Zakowski, M.F.7
Frankel, S.8
Peifer, M.9
Thomas, R.K.10
-
163
-
-
84855398829
-
Targeting the Insulin-like Growth Factor Axis for the Development of Novel Therapeutics in Oncology
-
Gao, J.; Chang, Y.S.; Jallal, B.; Viner, J. Targeting the Insulin-like Growth Factor Axis for the Development of Novel Therapeutics in Oncology. Cancer Res., 2012, 72 (1), 3-12.
-
(2012)
Cancer Res
, vol.72
, Issue.1
, pp. 3-12
-
-
Gao, J.1
Chang, Y.S.2
Jallal, B.3
Viner, J.4
-
164
-
-
36549015742
-
Insulin receptor structure and its implications for the IGF-1 receptor
-
Lawrence, M.C.; McKern, N.M.; Ward, C.W. Insulin receptor structure and its implications for the IGF-1 receptor. Curr. Opin. Struct. Biol., 2007, 17 (6), 699-705.
-
(2007)
Curr. Opin. Struct. Biol
, vol.17
, Issue.6
, pp. 699-705
-
-
Lawrence, M.C.1
McKern, N.M.2
Ward, C.W.3
-
165
-
-
0032560603
-
Molecular mimics of insulin-like growth factor 1 (IGF-1) for inhibiting IGF-1: IGF-binding protein interactions
-
Lowman, H.B.; Chen, Y.M.; Skelton, N.J.; Mortensen, D.L.; Tomlinson, E.E.; Sadick, M.D.; Robinson, I.C.A.F.; Clark, R.G. Molecular mimics of insulin-like growth factor 1 (IGF-1) for inhibiting IGF-1: IGF-binding protein interactions. Biochemistry (Mosc). 1998, 37 (25), 8870-8878.
-
(1998)
Biochemistry (Mosc)
, vol.37
, Issue.25
, pp. 8870-8878
-
-
Lowman, H.B.1
Chen, Y.M.2
Skelton, N.J.3
Mortensen, D.L.4
Tomlinson, E.E.5
Sadick, M.D.6
Robinson, I.C.A.F.7
Clark, R.G.8
-
166
-
-
0028271497
-
Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors
-
Resnicoff, M.; Sell, C.; Rubini, M.; Coppola, D.; Ambrose, D.; Baserga, R.; Rubin, R. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res., 1994, 54 (8), 2218.
-
(2218)
Cancer Res
, vol.54
, Issue.8
, pp. 1994
-
-
Resnicoff, M.1
Sell, C.2
Rubini, M.3
Coppola, D.4
Ambrose, D.5
Baserga, R.6
Rubin, R.7
-
167
-
-
0028050256
-
Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor
-
Resnicoff, M.; Coppola, D.; Sell, C.; Rubin, R.; Ferrone, S.; Baserga, R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res., 1994, 54 (18), 4848.
-
(1994)
Cancer Res
, vol.54
, Issue.18
, pp. 4848
-
-
Resnicoff, M.1
Coppola, D.2
Sell, C.3
Rubin, R.4
Ferrone, S.5
Baserga, R.6
-
168
-
-
0028920352
-
Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor
-
Long, L.; Rubin, R.; Baserga, R.; Brodt, P. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res., 1995, 55 (5), 1006.
-
(1995)
Cancer Res
, vol.55
, Issue.5
, pp. 1006
-
-
Long, L.1
Rubin, R.2
Baserga, R.3
Brodt, P.4
-
169
-
-
73449103570
-
Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer
-
Furukawa, J.; Wraight, C.J.; Freier, S.M.; Peralta, E.; Atley, L.M.; Monia, B.P.; Gleave, M.E.; Cox, M.E. Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer. The Prostate, 2010, 70 (2), 206-218.
-
(2010)
The Prostate
, vol.70
, Issue.2
, pp. 206-218
-
-
Furukawa, J.1
Wraight, C.J.2
Freier, S.M.3
Peralta, E.4
Atley, L.M.5
Monia, B.P.6
Gleave, M.E.7
Cox, M.E.8
-
170
-
-
41249093600
-
Role of insulin-like growth factor-1R system in colorectal carcinogenesis
-
Donovan, E.A.; Kummar, S. Role of insulin-like growth factor-1R system in colorectal carcinogenesis. Crit. Rev. Oncol./Hematol., 2008, 66 (2), 91-98.
-
(2008)
Crit. Rev. Oncol./Hematol
, vol.66
, Issue.2
, pp. 91-98
-
-
Donovan, E.A.1
Kummar, S.2
-
171
-
-
33947265626
-
In the absence of IGF-1 signaling, IFN-γ suppresses human malignant T-cell growth
-
Conti, L.; Regis, G.; Longo, A.; Bernabei, P.; Chiarle, R.; Giovarelli, M.; Novelli, F. In the absence of IGF-1 signaling, IFN-γ suppresses human malignant T-cell growth. Blood, 2007, 109 (6), 2496-2504.
-
(2007)
Blood
, vol.109
, Issue.6
, pp. 2496-2504
-
-
Conti, L.1
Regis, G.2
Longo, A.3
Bernabei, P.4
Chiarle, R.5
Giovarelli, M.6
Novelli, F.7
-
172
-
-
0034668185
-
Inhibition of the type I insulin-like growth factor receptor expression and signaling: Novel strategies for antimetastatic therapy
-
Brodt, P.; Samani, A.; Navab, R. Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy. Biochem. Pharmacol., 2000, 60 (8), 1101-1107.
-
(2000)
Biochem. Pharmacol
, vol.60
, Issue.8
, pp. 1101-1107
-
-
Brodt, P.1
Samani, A.2
Navab, R.3
-
173
-
-
0033179378
-
Expression of insulin-like growth factor-1 receptor in synovial sarcoma
-
Xie, Y.; Skytting, B.; Nilsson, G.; Brodin, B.; Larsson, O. Expression of insulin-like growth factor-1 receptor in synovial sarcoma. Cancer Res., 1999, 59 (15), 3588.
-
(1999)
Cancer Res
, vol.59
, Issue.15
, pp. 3588
-
-
Xie, Y.1
Skytting, B.2
Nilsson, G.3
Brodin, B.4
Larsson, O.5
-
174
-
-
57149127369
-
IGF-1 receptor inhibitors in clinical trials-early lessons
-
Weroha, S.J.; Haluska, P. IGF-1 receptor inhibitors in clinical trials-early lessons. J. Mammary Gland Biol. Neoplasia, 2008, 13 (4), 471-483.
-
(2008)
J. Mammary Gland Biol. Neoplasia
, vol.13
, Issue.4
, pp. 471-483
-
-
Weroha, S.J.1
Haluska, P.2
-
175
-
-
1642421788
-
The new kid on the blockade of the IGF-1 receptor
-
LeRoith, D.; Helman, L. The new kid on the blockade of the IGF-1 receptor. Cancer Cell, 2004, 5 (3), 201-202.
-
(2004)
Cancer Cell
, vol.5
, Issue.3
, pp. 201-202
-
-
Leroith, D.1
Helman, L.2
-
176
-
-
84855467975
-
The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology
-
Pollak, M. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin. Cancer Res., 2012, 18 (1), 40-50.
-
(2012)
Clin. Cancer Res
, vol.18
, Issue.1
, pp. 40-50
-
-
Pollak, M.1
-
177
-
-
69449097339
-
Emerging role of insulin-like growth factor receptor inhibitors in oncology: Early clinical trial results and future directions
-
Gualberto, A.; Pollak, M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene, 2009, 28 (34), 3009-3021.
-
(2009)
Oncogene
, vol.28
, Issue.34
, pp. 3009-3021
-
-
Gualberto, A.1
Pollak, M.2
-
178
-
-
79952284127
-
Hallmarks of cancer: The next generation
-
Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell, 2011, 144 (5), 646-674.
-
(2011)
Cell
, vol.144
, Issue.5
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.A.2
-
179
-
-
84877812176
-
-
Cancer Systems Biology, Bioinformatics and Medicine
-
Auffray, C.; Ideker, T.; Galas, D.J.; Hood, L. The Hallmarks of Cancer Revisited Through Systems Biology and Network Modelling. Cancer Systems Biology, Bioinformatics and Medicine, 2011, 245-266.
-
(2011)
The Hallmarks of Cancer Revisited Through Systems Biology and Network Modelling
, pp. 245-266
-
-
Auffray, C.1
Ideker, T.2
Galas, D.J.3
Hood, L.4
-
180
-
-
77952109477
-
Recent Progress in the Development of Small Molecule Inhibitors of Insulin-Like Growth Factor-1 Receptor Kinase
-
Wittman, M.D.; Velaparthi, U.; Vyas, D.M. Recent Progress in the Development of Small Molecule Inhibitors of Insulin-Like Growth Factor-1 Receptor Kinase. Annu. Rep. Med. Chem., 2009, 44, 281-299.
-
(2009)
Annu. Rep. Med. Chem
, vol.44
, pp. 281-299
-
-
Wittman, M.D.1
Velaparthi, U.2
Vyas, D.M.3
-
181
-
-
69049108757
-
Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach
-
Li, R.; Pourpak, A.; Morris, S.W. Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J. Med. Chem., 2009, 52 (16), 4981.
-
(2009)
J. Med. Chem
, vol.52
, Issue.16
, pp. 4981
-
-
Li, R.1
Pourpak, A.2
Morris, S.W.3
-
182
-
-
83455236504
-
Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
-
King, E.R.; Wong, K.K. Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy. Recent Pat. Anticancer Drug Discov., 2012, 7 (1), 14-30.
-
(2012)
Recent Pat. Anticancer Drug Discov
, vol.7
, Issue.1
, pp. 14-30
-
-
King, E.R.1
Wong, K.K.2
-
183
-
-
84875543855
-
Clinical development of insulin-like growth factor receptor-1 (IGF-1R) inhibitors: At the crossroad?
-
Gombos, A.; Metzger-Filho, O.; Dal Lago, L.; Awada-Hussein, A. Clinical development of insulin-like growth factor receptor-1 (IGF-1R) inhibitors: At the crossroad? Invest. New Drugs, 2012, 1-10.
-
(2012)
Invest. New Drugs
, pp. 1-10
-
-
Gombos, A.1
Metzger-Filho, O.2
Dal Lago, L.3
Awada-Hussein, A.4
-
184
-
-
84863900275
-
Insulin-like Growth Factor Receptor Inhibitors: Baby or the Bathwater?
-
Yee, D. Insulin-like Growth Factor Receptor Inhibitors: Baby or the Bathwater? J. Natl. Cancer Inst., 2012, 104 (13), 975-981.
-
(2012)
J. Natl. Cancer Inst
, vol.104
, Issue.13
, pp. 975-981
-
-
Yee, D.1
-
185
-
-
84861720634
-
Insulin-like Growth Factor-1 Receptor (IGF-1R) Kinase Inhibitorsin Cancer Therapy: Advances and Perspectives
-
Xue, M.; Cao, X.; Zhong, Y.; Kuang, D.; Liu, X.; Zhao, Z.; Li, H. Insulin-like Growth Factor-1 Receptor (IGF-1R) Kinase Inhibitorsin Cancer Therapy: Advances and Perspectives. Curr. Pharm. Des., 2012, 18 (20), 2901-2913.
-
(2012)
Curr. Pharm. Des
, vol.18
, Issue.20
, pp. 2901-2913
-
-
Xue, M.1
Cao, X.2
Zhong, Y.3
Kuang, D.4
Liu, X.5
Zhao, Z.6
Li, H.7
-
186
-
-
0034793734
-
Crystal Structure of Bisphosphorylated IGF-1 Receptor Kinase: Insight into Domain Movements upon Kinase Activation
-
Pautsch, A.; Zoephel, A.; Ahorn, H.; Spevak, W.; Hauptmann, R.; Nar, H. Crystal Structure of Bisphosphorylated IGF-1 Receptor Kinase: Insight into Domain Movements upon Kinase Activation. Structure, 2001, 9 (10), 955-965.
-
(2001)
Structure
, vol.9
, Issue.10
, pp. 955-965
-
-
Pautsch, A.1
Zoephel, A.2
Ahorn, H.3
Spevak, W.4
Hauptmann, R.5
Nar, H.6
-
187
-
-
65149102076
-
Discovery of 3, 5-disubstituted-1H-pyrrolo [2, 3-b] pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase
-
Patnaik, S.; Stevens, K.L.; Gerding, R.; Deanda, F.; Shotwell, J.B.; Tang, J.; Hamajima, T.; Nakamura, H.; Leesnitzer, M.A.; Hassell, A.M. Discovery of 3, 5-disubstituted-1H-pyrrolo [2, 3-b] pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase. Bioorg. Med. Chem. Lett., 2009, 19 (11), 3136-3140.
-
(2009)
Bioorg. Med. Chem. Lett
, vol.19
, Issue.11
, pp. 3136-3140
-
-
Patnaik, S.1
Stevens, K.L.2
Gerding, R.3
Deanda, F.4
Shotwell, J.B.5
Tang, J.6
Hamajima, T.7
Nakamura, H.8
Leesnitzer, M.A.9
Hassell, A.M.10
-
188
-
-
57749086732
-
Discovery of 4, 6-bis-anilino-1H-pyrrolo [2, 3-d] pyrimidines: Potent inhibitors of the IGF-1R receptor tyrosine kinase
-
Chamberlain, S.D.; Wilson, J.W.; Deanda, F.; Patnaik, S.; Redman, A.M.; Yang, B.; Shewchuk, L.; Sabbatini, P.; Leesnitzer, M.A.; Groy, A. Discovery of 4, 6-bis-anilino-1H-pyrrolo [2, 3-d] pyrimidines: potent inhibitors of the IGF-1R receptor tyrosine kinase. Bioorg. Med. Chem. Lett., 2009, 19 (2), 469-473.
-
(2009)
Bioorg. Med. Chem. Lett
, vol.19
, Issue.2
, pp. 469-473
-
-
Chamberlain, S.D.1
Wilson, J.W.2
Deanda, F.3
Patnaik, S.4
Redman, A.M.5
Yang, B.6
Shewchuk, L.7
Sabbatini, P.8
Leesnitzer, M.A.9
Groy, A.10
-
189
-
-
57749093097
-
Optimization of a series of 4, 6-bis-anilino-1h-pyrrolo [2, 3-d] pyrimidine inhibitors of igf-1r: Elimination of an acid-mediated decomposition pathway
-
Chamberlain, S.D.; Redman, A.M.; Patnaik, S.; Brickhouse, K.; Chew, Y.C.; Deanda, F.; Gerding, R.; Lei, H.; Moorthy, G.; Patrick, M. Optimization of a series of 4, 6-bis-anilino-1h-pyrrolo [2, 3-d] pyrimidine inhibitors of igf-1r: elimination of an acid-mediated decomposition pathway. Bioorg. Med. Chem. Lett., 2009, 19 (2), 373-377.
-
(2009)
Bioorg. Med. Chem. Lett
, vol.19
, Issue.2
, pp. 373-377
-
-
Chamberlain, S.D.1
Redman, A.M.2
Patnaik, S.3
Brickhouse, K.4
Chew, Y.C.5
Deanda, F.6
Gerding, R.7
Lei, H.8
Moorthy, G.9
Patrick, M.10
-
190
-
-
57949114351
-
Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment
-
Miller, L.M.; Mayer, S.C.; Berger, D.M.; Boschelli, D.H.; Boschelli, F.; Di, L.; Du, X.; Dutia, M.; Floyd, M.B.; Johnson, M. Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment. Bioorg. Med. Chem. Lett., 2009, 19 (1), 62-66.
-
(2009)
Bioorg. Med. Chem. Lett
, vol.19
, Issue.1
, pp. 62-66
-
-
Miller, L.M.1
Mayer, S.C.2
Berger, D.M.3
Boschelli, D.H.4
Boschelli, F.5
Di, L.6
Du, X.7
Dutia, M.8
Floyd, M.B.9
Johnson, M.10
-
191
-
-
44949188302
-
Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment
-
Mayer, S.C.; Banker, A.L.; Boschelli, F.; Di, L.; Johnson, M.; Kenny, C.H.; Krishnamurthy, G.; Kutterer, K.; Moy, F.; Petusky, S. Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment. Bioorg. Med. Chem. Lett., 2008, 18 (12), 3641-3645.
-
(2008)
Bioorg. Med. Chem. Lett
, vol.18
, Issue.12
, pp. 3641-3645
-
-
Mayer, S.C.1
Banker, A.L.2
Boschelli, F.3
Di, L.4
Johnson, M.5
Kenny, C.H.6
Krishnamurthy, G.7
Kutterer, K.8
Moy, F.9
Petusky, S.10
-
192
-
-
33947581423
-
Discovery and initial SAR of 3-(1H-benzo [d] imidazol-2-yl) pyridin-2 (1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R)
-
Velaparthi, U.; Wittman, M.; Liu, P.; Stoffan, K.; Zimmermann, K.; Sang, X.; Carboni, J.; Li, A.; Attar, R.; Gottardis, M. Discovery and initial SAR of 3-(1H-benzo [d] imidazol-2-yl) pyridin-2 (1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R). Bioorg. Med. Chem. Lett., 2007, 17 (8), 2317-2321.
-
(2007)
Bioorg. Med. Chem. Lett
, vol.17
, Issue.8
, pp. 2317-2321
-
-
Velaparthi, U.1
Wittman, M.2
Liu, P.3
Stoffan, K.4
Zimmermann, K.5
Sang, X.6
Carboni, J.7
Li, A.8
Attar, R.9
Gottardis, M.10
-
193
-
-
77955659488
-
Proline isosteres in a series of 2, 4-disubstituted pyrrolo [1, 2-f][1, 2, 4] triazine inhibitors of IGF-1R kinase and IR kinase
-
Sampognaro, A.J.; Wittman, M.D.; Carboni, J.M.; Chang, C.; Greer, A.F.; Hurlburt, W.W.; Sack, J.S.; Vyas, D.M. Proline isosteres in a series of 2, 4-disubstituted pyrrolo [1, 2-f][1, 2, 4] triazine inhibitors of IGF-1R kinase and IR kinase. Bioorg. Med. Chem. Lett., 2010, 20 (17), 5027-5030.
-
(2010)
Bioorg. Med. Chem. Lett
, vol.20
, Issue.17
, pp. 5027-5030
-
-
Sampognaro, A.J.1
Wittman, M.D.2
Carboni, J.M.3
Chang, C.4
Greer, A.F.5
Hurlburt, W.W.6
Sack, J.S.7
Vyas, D.M.8
-
194
-
-
58149311431
-
Identification of a key element for hydrogen-bonding patterns between protein kinases and their inhibitors
-
Katayama, N.; Orita, M.; Yamaguchi, T.; Hisamichi, H.; Kuromitsu, S.; Kurihara, H.; Sakashita, H.; Matsumoto, Y.; Fujita, S.; Niimi, T. Identification of a key element for hydrogen-bonding patterns between protein kinases and their inhibitors. Proteins: Struct., Funct., Bioinf., 2008, 73 (4), 795-801.
-
(2008)
Proteins: Struct., Funct., Bioinf
, vol.73
, Issue.4
, pp. 795-801
-
-
Katayama, N.1
Orita, M.2
Yamaguchi, T.3
Hisamichi, H.4
Kuromitsu, S.5
Kurihara, H.6
Sakashita, H.7
Matsumoto, Y.8
Fujita, S.9
Niimi, T.10
-
195
-
-
79953271287
-
Discovery of 2, 4-bis-arylamino-1, 3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors
-
Buchanan, J.L.; Newcomb, J.R.; Carney, D.P.; Chaffee, S.C.; Chai, L.; Cupples, R.; Epstein, L.F.; Gallant, P.; Gu, Y.; Harmange, J.C. Discovery of 2, 4-bis-arylamino-1, 3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors. Bioorg. Med. Chem. Lett., 2011, 21 (8), 2394-2399.
-
(2011)
Bioorg. Med. Chem. Lett
, vol.21
, Issue.8
, pp. 2394-2399
-
-
Buchanan, J.L.1
Newcomb, J.R.2
Carney, D.P.3
Chaffee, S.C.4
Chai, L.5
Cupples, R.6
Epstein, L.F.7
Gallant, P.8
Gu, Y.9
Harmange, J.C.10
-
196
-
-
77954360109
-
Design of Potent IGF1-R Inhibitors Related to Bis-azaindoles
-
Nemecek, C.; Metz, W.A.; Wentzler, S.; Ding, F.X.; Venot, C.; Souaille, C.; Dagallier, A.; Maignan, S.; Guilloteau, J.P.; Bernard, F. Design of Potent IGF1-R Inhibitors Related to Bis-azaindoles. Chemical Biology & Drug Design, 2010, 76 (2), 100-106.
-
(2010)
Chemical Biology & Drug Design
, vol.76
, Issue.2
, pp. 100-106
-
-
Nemecek, C.1
Metz, W.A.2
Wentzler, S.3
Ding, F.X.4
Venot, C.5
Souaille, C.6
Dagallier, A.7
Maignan, S.8
Guilloteau, J.P.9
Bernard, F.10
-
197
-
-
79953291096
-
Discovery of the first non ATP competitive IGF-1R kinase inhibitors: Advantages in comparison with competitive inhibitors
-
Lesuisse, D.; Mauger, J.; Nemecek, C.; Maignan, S.; Boiziau, J.; Harlow, G.; Hittinger, A.; Ruf, S.; Strobel, H.; Nair, A. Discovery of the first non ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors. Bioorg. Med. Chem. Lett., 2011, 21 (8), 2224-2228.
-
(2011)
Bioorg. Med. Chem. Lett
, vol.21
, Issue.8
, pp. 2224-2228
-
-
Lesuisse, D.1
Mauger, J.2
Nemecek, C.3
Maignan, S.4
Boiziau, J.5
Harlow, G.6
Hittinger, A.7
Ruf, S.8
Strobel, H.9
Nair, A.10
-
198
-
-
77956136788
-
Allosteric IGF-1R Inhibitors
-
Heinrich, T.; Grädler, U.; Böttcher, H.; Blaukat, A.; Shutes, A. Allosteric IGF-1R Inhibitors. ACS Med. Chem. Lett., 2010, 1 (5), 199-203.
-
(2010)
ACS Med. Chem. Lett
, vol.1
, Issue.5
, pp. 199-203
-
-
Heinrich, T.1
Grädler, U.2
Böttcher, H.3
Blaukat, A.4
Shutes, A.5
-
199
-
-
72249089981
-
Discovery of a 2, 4-disubstituted pyrrolo [1, 2-f][1, 2, 4] triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development
-
Wittman, M.D.; Carboni, J.M.; Yang, Z.; Lee, F.Y.; Antman, M.; Attar, R.; Balimane, P.; Chang, C.; Chen, C.; Discenza, L. Discovery of a 2, 4-disubstituted pyrrolo [1, 2-f][1, 2, 4] triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development. J. Med. Chem., 2009, 52 (23), 7360-7363.
-
(2009)
J. Med. Chem
, vol.52
, Issue.23
, pp. 7360-7363
-
-
Wittman, M.D.1
Carboni, J.M.2
Yang, Z.3
Lee, F.Y.4
Antman, M.5
Attar, R.6
Balimane, P.7
Chang, C.8
Chen, C.9
Discenza, L.10
-
200
-
-
47949113688
-
Small-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor
-
Wu, J.; Li, W.; Craddock, B.P.; Foreman, K.W.; Mulvihill, M.J.; Ji, Q.; Miller, W.T.; Hubbard, S.R. Small-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor. EMBO J., 2008, 27 (14), 1985-1994.
-
(2008)
EMBO J
, vol.27
, Issue.14
, pp. 1985-1994
-
-
Wu, J.1
Li, W.2
Craddock, B.P.3
Foreman, K.W.4
Mulvihill, M.J.5
Ji, Q.6
Miller, W.T.7
Hubbard, S.R.8
-
201
-
-
84877798688
-
-
S. 2005/0153989. July 14
-
Milanov, Z.V.; Mehta, S.A.; Lai, A.G.; Patel, H.K.; Grotzfeld, R.M.; Lockhart, D.J. Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases. U.S. 2005/0153989. July 14 2005.
-
(2005)
Pyrrolopyrimidine Derivatives and Analogs and Their Use in the Treatment and Prevention of Diseases
-
-
Milanov, Z.V.1
Mehta, S.A.2
Lai, A.G.3
Patel, H.K.4
Grotzfeld, R.M.5
Lockhart, D.J.6
-
202
-
-
20944447905
-
Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors
-
Scotlandi, K.; Manara, M.C.; Nicoletti, G.; Lollini, P.L.; Lukas, S.; Benini, S.; Croci, S.; Perdichizzi, S.; Zambelli, D.; Serra, M. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res., 2005, 65 (9), 3868.
-
(2005)
Cancer Res
, vol.65
, Issue.9
, pp. 3868
-
-
Scotlandi, K.1
Manara, M.C.2
Nicoletti, G.3
Lollini, P.L.4
Lukas, S.5
Benini, S.6
Croci, S.7
Perdichizzi, S.8
Zambelli, D.9
Serra, M.10
-
203
-
-
12144285705
-
In vivo antitumor activity of NVP-AEW541--A novel, potent, and selective inhibitor of the IGF-IR kinase
-
Garci'a-Echeverri'a, C.; Pearson, M.A.; Marti, A.; Meyer, T.; Mestan, J.; Zimmermann, J.; Gao, J.; Brueggen, J.; Capraro, H.G.; Cozens, R. In vivo antitumor activity of NVP-AEW541--A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell, 2004, 5 (3), 231-239.
-
(2004)
Cancer Cell
, vol.5
, Issue.3
, pp. 231-239
-
-
Garci'a-Echeverri'a, C.1
Pearson, M.A.2
Marti, A.3
Meyer, T.4
Mestan, J.5
Zimmermann, J.6
Gao, J.7
Brueggen, J.8
Capraro, H.G.9
Cozens, R.10
-
204
-
-
14644433735
-
The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy
-
Warshamana-Greene, G.S.; Litz, J.; Buchdunger, E.; García-Echeverría, C.; Hofmann, F.; Krystal, G.W. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin. Cancer Res., 2005, 11 (4), 1563-1571.
-
(2005)
Clin. Cancer Res
, vol.11
, Issue.4
, pp. 1563-1571
-
-
Warshamana-Greene, G.S.1
Litz, J.2
Buchdunger, E.3
García-Echeverría, C.4
Hofmann, F.5
Krystal, G.W.6
-
205
-
-
33947262154
-
Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma
-
Manara, M.C.; Landuzzi, L.; Nanni, P.; Nicoletti, G.; Zambelli, D.; Lollini, P.L.; Nanni, C.; Hofmann, F.; García-Echeverría, C.; Picci, P. Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma. Clin. Cancer Res., 2007, 13 (4), 1322-1330.
-
(2007)
Clin. Cancer Res
, vol.13
, Issue.4
, pp. 1322-1330
-
-
Manara, M.C.1
Landuzzi, L.2
Nanni, P.3
Nicoletti, G.4
Zambelli, D.5
Lollini, P.L.6
Nanni, C.7
Hofmann, F.8
García-Echeverría, C.9
Picci, P.10
-
206
-
-
42249114184
-
The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells
-
Maiso, P.; Ocio, E.M.; Garayoa, M.; Montero, J.C.; Hofmann, F.; García-Echeverría, C.; Zimmermann, J.; Pandiella, A.; San Miguel, J.F. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. Br. J. Haematol., 2008, 141 (4), 470-482.
-
(2008)
Br. J. Haematol
, vol.141
, Issue.4
, pp. 470-482
-
-
Maiso, P.1
Ocio, E.M.2
Garayoa, M.3
Montero, J.C.4
Hofmann, F.5
García-Echeverría, C.6
Zimmermann, J.7
Pandiella, A.8
San Miguel, J.F.9
-
207
-
-
57749094579
-
Optimization of 4, 6-bis-anilino-1H-pyrrolo [2, 3-d] pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity
-
Chamberlain, S.D.; Redman, A.M.; Wilson, J.W.; Deanda, F.; Shotwell, J.B.; Gerding, R.; Lei, H.; Yang, B.; Stevens, K.L.; Hassell, A.M. Optimization of 4, 6-bis-anilino-1H-pyrrolo [2, 3-d] pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity. Bioorg. Med. Chem. Lett., 2009, 19 (2), 360-364.
-
(2009)
Bioorg. Med. Chem. Lett
, vol.19
, Issue.2
, pp. 360-364
-
-
Chamberlain, S.D.1
Redman, A.M.2
Wilson, J.W.3
Deanda, F.4
Shotwell, J.B.5
Gerding, R.6
Lei, H.7
Yang, B.8
Stevens, K.L.9
Hassell, A.M.10
-
208
-
-
61349088756
-
Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases
-
Hubbard, R.D.; Bamaung, N.Y.; Fidanze, S.D.; Erickson, S.A.; Palazzo, F.; Wilsbacher, J.L.; Zhang, Q.; Tucker, L.A.; Hu, X.; Kovar, P. Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases. Bioorg. Med. Chem. Lett., 2009, 19 (6), 1718-1721.
-
(2009)
Bioorg. Med. Chem. Lett
, vol.19
, Issue.6
, pp. 1718-1721
-
-
Hubbard, R.D.1
Bamaung, N.Y.2
Fidanze, S.D.3
Erickson, S.A.4
Palazzo, F.5
Wilsbacher, J.L.6
Zhang, Q.7
Tucker, L.A.8
Hu, X.9
Kovar, P.10
-
209
-
-
77956898555
-
Substituted 4-amino-1H-pyrazolo [3, 4-d] pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases
-
Wang, G.T.; Mantei, R.A.; Hubbard, R.D.; Wilsbacher, J.L.; Zhang, Q.; Tucker, L.; Hu, X.; Kovar, P.; Johnson, E.F.; Osterling, D.J. Substituted 4-amino-1H-pyrazolo [3, 4-d] pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases. Bioorg. Med. Chem. Lett., 2010, 20 (20), 6067-6071.
-
(2010)
Bioorg. Med. Chem. Lett
, vol.20
, Issue.20
, pp. 6067-6071
-
-
Wang, G.T.1
Mantei, R.A.2
Hubbard, R.D.3
Wilsbacher, J.L.4
Zhang, Q.5
Tucker, L.6
Hu, X.7
Kovar, P.8
Johnson, E.F.9
Osterling, D.J.10
-
210
-
-
33846615796
-
1, 3-Disubstituted-imidazo [1, 5-a] pyrazines as insulin-like growth-factor-I receptor (IGF-IR) inhibitors
-
Mulvihill, M.J.; Ji, Q.S.; Werner, D.; Beck, P.; Cesario, C.; Cooke, A.; Cox, M.; Crew, A.; Dong, H.; Feng, L. 1, 3-Disubstituted-imidazo [1, 5-a] pyrazines as insulin-like growth-factor-I receptor (IGF-IR) inhibitors. Bioorg. Med. Chem. Lett., 2007, 17 (4), 1091-1097.
-
(2007)
Bioorg. Med. Chem. Lett
, vol.17
, Issue.4
, pp. 1091-1097
-
-
Mulvihill, M.J.1
Ji, Q.S.2
Werner, D.3
Beck, P.4
Cesario, C.5
Cooke, A.6
Cox, M.7
Crew, A.8
Dong, H.9
Feng, L.10
-
211
-
-
38849133610
-
Novel 2-phenylquinolin-7-yl-derived imidazo [1, 5-a] pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors
-
Mulvihill, M.J.; Ji, Q.S.; Coate, H.R.; Cooke, A.; Dong, H.; Feng, L.; Foreman, K.; Honda, A.; Mak, G.; Mulvihill, K.M. Novel 2-phenylquinolin-7-yl-derived imidazo [1, 5-a] pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors. Biorg. Med. Chem., 2008, 16 (3), 1359-1375.
-
(2008)
Biorg. Med. Chem
, vol.16
, Issue.3
, pp. 1359-1375
-
-
Mulvihill, M.J.1
Ji, Q.S.2
Coate, H.R.3
Cooke, A.4
Dong, H.5
Feng, L.6
Foreman, K.7
Honda, A.8
Mak, G.9
Mulvihill, K.M.10
-
212
-
-
34548058890
-
A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor-dependent tumor growth in vivo
-
Ji, Q.; Mulvihill, M.J.; Cooke, A.; Feng, L.; Mak, G.; O'Connor, M.; Yao, Y.; Pirritt, C.; Buck, E.; Eyzaguirre, A. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor-dependent tumor growth in vivo. Mol. Cancer Ther., 2007, 6 (8), 2158.
-
(2158)
Mol. Cancer Ther
, vol.6
, Issue.8
, pp. 2007
-
-
Ji, Q.1
Mulvihill, M.J.2
Cooke, A.3
Feng, L.4
Mak, G.5
O'Connor, M.6
Yao, Y.7
Pirritt, C.8
Buck, E.9
Eyzaguirre, A.10
-
213
-
-
77952060250
-
Discovery of OSI-906: A selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor
-
Mulvihill, M.J.; Cooke, A.; Buck, E.; Foreman, K.; Landfair, D.; O'Connor, M.; Pirritt, C.; Sun, Y.; Yao, Y.; Arnold, L.D. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med. Chem., 2009, 1 (6), 1153-1171.
-
(2009)
Future Med. Chem
, vol.1
, Issue.6
, pp. 1153-1171
-
-
Mulvihill, M.J.1
Cooke, A.2
Buck, E.3
Foreman, K.4
Landfair, D.5
O'Connor, M.6
Pirritt, C.7
Sun, Y.8
Yao, Y.9
Arnold, L.D.10
-
214
-
-
79851513257
-
Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy
-
Jin, M.; Kleinberg, A.; Cooke, A.; Gokhale, P.C.; Foreman, K.; Dong, H.; Siu, K.W.; Bittner, M.A.; Mulvihill, K.M.; Yao, Y. Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy. Bioorg. Med. Chem. Lett., 2011, 21 (4), 1176-1180.
-
(2011)
Bioorg. Med. Chem. Lett
, vol.21
, Issue.4
, pp. 1176-1180
-
-
Jin, M.1
Kleinberg, A.2
Cooke, A.3
Gokhale, P.C.4
Foreman, K.5
Dong, H.6
Siu, K.W.7
Bittner, M.A.8
Mulvihill, K.M.9
Yao, Y.10
-
215
-
-
84887160552
-
-
Huang, X.; Aslanian, R.G., Ed.; Wiley & Sons, New Jersey
-
Jin, M.; Buck, E.; Mulvihill, M.J. In: Case Studies in Modern Drug Discovery and Development; Huang, X.; Aslanian, R.G., Ed.; Wiley & Sons, New Jersey, 2012, pp. 127-148.
-
(2012)
Case Studies in Modern Drug Discovery and Development
, pp. 127-148
-
-
Jin, M.1
Buck, E.2
Mulvihill, M.J.3
-
216
-
-
58549088976
-
Discovery and optimization of imidazo [1, 2-a] pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R)
-
Emmitte, K.A.; Wilson, B.J.; Baum, E.W.; Emerson, H.K.; Kuntz, K.W.; Nailor, K.E.; Salovich, J.M.; Smith, S.C.; Cheung, M.; Gerding, R.M. Discovery and optimization of imidazo [1, 2-a] pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R). Bioorg. Med. Chem. Lett., 2009, 19 (3), 1004-1008.
-
(2009)
Bioorg. Med. Chem. Lett
, vol.19
, Issue.3
, pp. 1004-1008
-
-
Emmitte, K.A.1
Wilson, B.J.2
Baum, E.W.3
Emerson, H.K.4
Kuntz, K.W.5
Nailor, K.E.6
Salovich, J.M.7
Smith, S.C.8
Cheung, M.9
Gerding, R.M.10
-
217
-
-
12444257368
-
Imidazo [1, 2-a] pyridines: A potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation
-
Anderson, M.; Beattie, J.F.; Breault, G.A.; Breed, J.; Byth, K.F.; Culshaw, J.D.; Ellston, R.; Green, S.; Minshull, C.A.; Norman, R.A. Imidazo [1, 2-a] pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation. Bioorg. Med. Chem. Lett., 2003, 13 (18), 3021-3026.
-
(2003)
Bioorg. Med. Chem. Lett
, vol.13
, Issue.18
, pp. 3021-3026
-
-
Anderson, M.1
Beattie, J.F.2
Breault, G.A.3
Breed, J.4
Byth, K.F.5
Culshaw, J.D.6
Ellston, R.7
Green, S.8
Minshull, C.A.9
Norman, R.A.10
-
218
-
-
1842639592
-
Imidazo [1, 2-a] pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors
-
Byth, K.F.; Culshaw, J.D.; Green, S.; Oakes, S.E.; Thomas, A.P. Imidazo [1, 2-a] pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors. Bioorg. Med. Chem. Lett., 2004, 14 (9), 2245-2248.
-
(2004)
Bioorg. Med. Chem. Lett
, vol.14
, Issue.9
, pp. 2245-2248
-
-
Byth, K.F.1
Culshaw, J.D.2
Green, S.3
Oakes, S.E.4
Thomas, A.P.5
-
219
-
-
79960918946
-
Discovery of novel imidazo [1, 2-a] pyridines as inhibitors of the insulin-like growth factor-1 receptor tyrosine kinase
-
Ducray, R.; Simpson, I.; Jung, F.H.; Nissink, J.W.M.; Kenny, P.W.; Fitzek, M.; Walker, G.E.; Ward, L.T.; Hudson, K. Discovery of novel imidazo [1, 2-a] pyridines as inhibitors of the insulin-like growth factor-1 receptor tyrosine kinase. Bioorg. Med. Chem. Lett., 2011, 21 (16), 4698-4701.
-
(2011)
Bioorg. Med. Chem. Lett
, vol.21
, Issue.16
, pp. 4698-4701
-
-
Ducray, R.1
Simpson, I.2
Jung, F.H.3
Nissink, J.W.M.4
Kenny, P.W.5
Fitzek, M.6
Walker, G.E.7
Ward, L.T.8
Hudson, K.9
-
220
-
-
79960927448
-
Novel imidazo [1, 2-a] pyridine based inhibitors of the IGF-1 receptor tyrosine kinase: Optimization of the aniline
-
Ducray, R.; Jones, C.D.; Jung, F.H.; Simpson, I.; Curwen, J.; Pass, M. Novel imidazo [1, 2-a] pyridine based inhibitors of the IGF-1 receptor tyrosine kinase: Optimization of the aniline. Bioorg. Med. Chem. Lett., 2011, 21 (16), 4702-4704.
-
(2011)
Bioorg. Med. Chem. Lett
, vol.21
, Issue.16
, pp. 4702-4704
-
-
Ducray, R.1
Jones, C.D.2
Jung, F.H.3
Simpson, I.4
Curwen, J.5
Pass, M.6
-
221
-
-
24744437999
-
Discovery of a 1 H-Benzoimidazol-2-yl)-1 H-pyridin-2-one (BMS-536924) Inhibitor of Insulin-like Growth Factor I Receptor Kinase with in Vivo Antitumor Activity
-
Wittman, M.; Carboni, J.; Attar, R.; Balasubramanian, B.; Balimane, P.; Brassil, P.; Beaulieu, F.; Chang, C.; Clarke, W.; Dell, J. Discovery of a 1 H-Benzoimidazol-2-yl)-1 H-pyridin-2-one (BMS-536924) Inhibitor of Insulin-like Growth Factor I Receptor Kinase with in Vivo Antitumor Activity. J. Med. Chem., 2005, 48 (18), 5639-5643.
-
(2005)
J. Med. Chem
, vol.48
, Issue.18
, pp. 5639-5643
-
-
Wittman, M.1
Carboni, J.2
Attar, R.3
Balasubramanian, B.4
Balimane, P.5
Brassil, P.6
Beaulieu, F.7
Chang, C.8
Clarke, W.9
Dell, J.10
-
222
-
-
33846607237
-
Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase
-
Wittman, M.D.; Balasubramanian, B.; Stoffan, K.; Velaparthi, U.; Liu, P.; Krishnanathan, S.; Carboni, J.; Li, A.; Greer, A.; Attar, R. Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase. Bioorg. Med. Chem. Lett., 2007, 17 (4), 974-977.
-
(2007)
Bioorg. Med. Chem. Lett
, vol.17
, Issue.4
, pp. 974-977
-
-
Wittman, M.D.1
Balasubramanian, B.2
Stoffan, K.3
Velaparthi, U.4
Liu, P.5
Krishnanathan, S.6
Carboni, J.7
Li, A.8
Greer, A.9
Attar, R.10
-
223
-
-
34247844537
-
Imidazole moiety replacements in the 3-(1H-benzo [d] imidazol-2-yl) pyridin-2 (1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile
-
Velaparthi, U.; Liu, P.; Balasubramanian, B.; Carboni, J.; Attar, R.; Gottardis, M.; Li, A.; Greer, A.; Zoeckler, M.; Wittman, M.D. Imidazole moiety replacements in the 3-(1H-benzo [d] imidazol-2-yl) pyridin-2 (1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile. Bioorg. Med. Chem. Lett., 2007, 17 (11), 3072-3076.
-
(2007)
Bioorg. Med. Chem. Lett
, vol.17
, Issue.11
, pp. 3072-3076
-
-
Velaparthi, U.1
Liu, P.2
Balasubramanian, B.3
Carboni, J.4
Attar, R.5
Gottardis, M.6
Li, A.7
Greer, A.8
Zoeckler, M.9
Wittman, M.D.10
-
224
-
-
84862907716
-
IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer
-
Dool, C.J.; Mashhedi, H.; Zakikhani, M.; David, S.; Zhao, Y.; Birman, E.; Carboni, J.M.; Gottardis, M.; Blouin, M.J.; Pollak, M. IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer. Endocr. Relat. Cancer, 2011, 18 (6), 699-709.
-
(2011)
Endocr. Relat. Cancer
, vol.18
, Issue.6
, pp. 699-709
-
-
Dool, C.J.1
Mashhedi, H.2
Zakikhani, M.3
David, S.4
Zhao, Y.5
Birman, E.6
Carboni, J.M.7
Gottardis, M.8
Blouin, M.J.9
Pollak, M.10
-
225
-
-
31544464616
-
In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417
-
Haluska, P.; Carboni, J.M.; Loegering, D.A.; Lee, F.Y.; Wittman, M.; Saulnier, M.G.; Frennesson, D.B.; Kalli, K.R.; Conover, C.A.; Attar, R.M. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res., 2006, 66 (1), 362.
-
(2006)
Cancer Res
, vol.66
, Issue.1
, pp. 362
-
-
Haluska, P.1
Carboni, J.M.2
Loegering, D.A.3
Lee, F.Y.4
Wittman, M.5
Saulnier, M.G.6
Frennesson, D.B.7
Kalli, K.R.8
Conover, C.A.9
Attar, R.M.10
-
226
-
-
53549109444
-
Discovery and Evaluation of 4-(2-(4-chloro-1 H-pyrazol-1-yl) ethylamino)-3-(6-(1-(3-fluoropropyl) piperidin-4-yl)-4-methyl-1 H-benzo [d] imidazol-2-yl) pyridin-2 (1 H)-one (BMS-695735), an Orally Efficacious Inhibitor of Insulin-like Growth Factor-1 Receptor Kinase with Broad Spectrum in Vivo Antitumor Activity
-
Velaparthi, U.; Wittman, M.; Liu, P.; Carboni, J.M.; Lee, F.Y.; Attar, R.; Balimane, P.; Clarke, W.; Sinz, M.W.; Hurlburt, W. Discovery and Evaluation of 4-(2-(4-chloro-1 H-pyrazol-1-yl) ethylamino)-3-(6-(1-(3-fluoropropyl) piperidin-4-yl)-4-methyl-1 H-benzo [d] imidazol-2-yl) pyridin-2 (1 H)-one (BMS-695735), an Orally Efficacious Inhibitor of Insulin-like Growth Factor-1 Receptor Kinase with Broad Spectrum in Vivo Antitumor Activity. J. Med. Chem., 2008, 51 (19), 5897-5900.
-
(2008)
J. Med. Chem
, vol.51
, Issue.19
, pp. 5897-5900
-
-
Velaparthi, U.1
Wittman, M.2
Liu, P.3
Carboni, J.M.4
Lee, F.Y.5
Attar, R.6
Balimane, P.7
Clarke, W.8
Sinz, M.W.9
Hurlburt, W.10
-
227
-
-
77952110655
-
Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one
-
Velaparthi, U.; Saulnier, M.G.; Wittman, M.D.; Liu, P.; Frennesson, D.B.; Zimmermann, K.; Carboni, J.M.; Gottardis, M.; Li, A.; Greer, A. Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one. Bioorg. Med. Chem. Lett., 2010, 20 (10), 3182-3185.
-
(2010)
Bioorg. Med. Chem. Lett
, vol.20
, Issue.10
, pp. 3182-3185
-
-
Velaparthi, U.1
Saulnier, M.G.2
Wittman, M.D.3
Liu, P.4
Frennesson, D.B.5
Zimmermann, K.6
Carboni, J.M.7
Gottardis, M.8
Li, A.9
Greer, A.10
-
228
-
-
33750081128
-
Parallel synthesis of diarylureas and their evaluation as inhibitors of insulin-like growth factor receptor
-
Anderson, M.O.; Yu, H.; Penaranda, C.; Maddux, B.A.; Goldfine, I.D.; Youngren, J.F.; Guy, R.K. Parallel synthesis of diarylureas and their evaluation as inhibitors of insulin-like growth factor receptor. J. Comb. Chem., 2006, 8 (5), 784-790.
-
(2006)
J. Comb. Chem
, vol.8
, Issue.5
, pp. 784-790
-
-
Anderson, M.O.1
Yu, H.2
Penaranda, C.3
Maddux, B.A.4
Goldfine, I.D.5
Youngren, J.F.6
Guy, R.K.7
-
229
-
-
33646595317
-
Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth
-
Gable, K.L.; Maddux, B.A.; Penaranda, C.; Zavodovskaya, M.; Campbell, M.J.; Lobo, M.; Robinson, L.; Schow, S.; Kerner, J.A.; Goldfine, I.D. Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth. Mol. Cancer Ther., 2006, 5 (4), 1079.
-
(2006)
Mol. Cancer Ther
, vol.5
, Issue.4
, pp. 1079
-
-
Gable, K.L.1
Maddux, B.A.2
Penaranda, C.3
Zavodovskaya, M.4
Campbell, M.J.5
Lobo, M.6
Robinson, L.7
Schow, S.8
Kerner, J.A.9
Goldfine, I.D.10
-
230
-
-
77955468949
-
Synthesis of aryl-heteroaryl ureas (AHUs) based on 4-aminoquinoline and their evaluation against the insulin-like growth factor receptor (IGF-1R)
-
Engen, W.; O'Brien, T.E.; Kelly, B.; Do, J.; Rillera, L.; Stapleton, L.K.; Youngren, J.F.; Anderson, M.O. Synthesis of aryl-heteroaryl ureas (AHUs) based on 4-aminoquinoline and their evaluation against the insulin-like growth factor receptor (IGF-1R). Biorg. Med. Chem., 2010, 18 (16), 5995-6005.
-
(2010)
Biorg. Med. Chem
, vol.18
, Issue.16
, pp. 5995-6005
-
-
Engen, W.1
O'Brien, T.E.2
Kelly, B.3
Do, J.4
Rillera, L.5
Stapleton, L.K.6
Youngren, J.F.7
Anderson, M.O.8
-
231
-
-
79957474318
-
Dual Igf-1r/Src Inhibitors Based On A N'-Aroyl-2-(1H-Indol-3-Yl)-2-Oxoacetohydrazide Structure
-
Schmidt, S.; Preu, L.; Lemcke, T.; Totzke, F.; Schächtele, C.; Kubbutat, M.H.G.; Kunick, C. Dual Igf-1r/Src Inhibitors Based On A N'-Aroyl-2-(1H-Indol-3-Yl)-2-Oxoacetohydrazide Structure. Eur. J. Med. Chem., 2011, 46 (7), 2759-2769.
-
(2011)
Eur. J. Med. Chem
, vol.46
, Issue.7
, pp. 2759-2769
-
-
Schmidt, S.1
Preu, L.2
Lemcke, T.3
Totzke, F.4
Schächtele, C.5
Kubbutat, M.H.G.6
Kunick, C.7
-
232
-
-
77953126861
-
Serotonin derivatives as a new class of non-ATP-competitive receptor tyrosine kinase inhibitors
-
Büttner, A.; Cottin, T.; Xu, J.; Tzagkaroulaki, L.; Giannis, A. Serotonin derivatives as a new class of non-ATP-competitive receptor tyrosine kinase inhibitors. Biorg. Med. Chem., 2010, 18 (10), 3387-3402.
-
(2010)
Biorg. Med. Chem
, vol.18
, Issue.10
, pp. 3387-3402
-
-
Büttner, A.1
Cottin, T.2
Xu, J.3
Tzagkaroulaki, L.4
Giannis, A.5
-
233
-
-
0025668424
-
Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors
-
Geissler, J.; Traxler, P.; Regenass, U.; Murray, B.; Roesel, J.; Meyer, T.; McGlynn, E.; Storni, A.; Lydon, N. Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors. J. Biol. Chem., 1990, 265 (36), 22255.
-
(1990)
J. Biol. Chem
, vol.265
, Issue.36
, pp. 22255
-
-
Geissler, J.1
Traxler, P.2
Regenass, U.3
Murray, B.4
Roesel, J.5
Meyer, T.6
McGlynn, E.7
Storni, A.8
Lydon, N.9
-
234
-
-
0035998737
-
Physiological and therapeutic roles of peroxisome proliferator-activated receptors
-
Berger, J.; Wagner, J.A. Physiological and therapeutic roles of peroxisome proliferator-activated receptors. Diabetes Technol. Ther., 2002, 4 (2), 163-174.
-
(2002)
Diabetes Technol. Ther
, vol.4
, Issue.2
, pp. 163-174
-
-
Berger, J.1
Wagner, J.A.2
-
235
-
-
24744435115
-
Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis
-
Camps, M.; Rückle, T.; Ji, H.; Ardissone, V.; Rintelen, F.; Shaw, J.; Ferrandi, C.; Chabert, C.; Gillieron, C.; Françon, B. Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med., 2005, 11 (9), 936-943.
-
(2005)
Nat. Med
, vol.11
, Issue.9
, pp. 936-943
-
-
Camps, M.1
Rückle, T.2
Ji, H.3
Ardissone, V.4
Rintelen, F.5
Shaw, J.6
Ferrandi, C.7
Chabert, C.8
Gillieron, C.9
Françon, B.10
-
236
-
-
33745662579
-
Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase γ
-
Pomel, V.; Klicic, J.; Covini, D.; Church, D.D.; Shaw, J.P.; Roulin, K.; Burgat-Charvillon, F.; Valognes, D.; Camps, M.; Chabert, C. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase γ. J. Med. Chem., 2006, 49 (13), 3857-3871.
-
(2006)
J. Med. Chem
, vol.49
, Issue.13
, pp. 3857-3871
-
-
Pomel, V.1
Klicic, J.2
Covini, D.3
Church, D.D.4
Shaw, J.P.5
Roulin, K.6
Burgat-Charvillon, F.7
Valognes, D.8
Camps, M.9
Chabert, C.10
-
237
-
-
72249122328
-
Design, Synthesis, and Structure? Activity Relationship of a Novel Series of 2-Aryl 5-(4-Oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl) furans as HIV-1 Entry Inhibitors?
-
Katritzky, A.R.; Tala, S.R.; Lu, H.; Vakulenko, A.V.; Chen, Q.Y.; Sivapackiam, J.; Pandya, K.; Jiang, S.; Debnath, A.K. Design, Synthesis, and Structure? Activity Relationship of a Novel Series of 2-Aryl 5-(4-Oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl) furans as HIV-1 Entry Inhibitors?. J. Med. Chem., 2009, 52 (23), 7631-7639.
-
(2009)
J. Med. Chem
, vol.52
, Issue.23
, pp. 7631-7639
-
-
Katritzky, A.R.1
Tala, S.R.2
Lu, H.3
Vakulenko, A.V.4
Chen, Q.Y.5
Sivapackiam, J.6
Pandya, K.7
Jiang, S.8
Debnath, A.K.9
-
238
-
-
67649307131
-
Novel benzylidene-thiazolidine-2, 4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells
-
Beharry, Z.; Zemskova, M.; Mahajan, S.; Zhang, F.; Ma, J.; Xia, Z.; Lilly, M.; Smith, C.D.; Kraft, A.S. Novel benzylidene-thiazolidine-2, 4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol. Cancer Ther., 2009, 8 (6), 1473-1483.
-
(2009)
Mol. Cancer Ther
, vol.8
, Issue.6
, pp. 1473-1483
-
-
Beharry, Z.1
Zemskova, M.2
Mahajan, S.3
Zhang, F.4
Ma, J.5
Xia, Z.6
Lilly, M.7
Smith, C.D.8
Kraft, A.S.9
-
239
-
-
77949859256
-
Discovery and SAR of thiazolidine-2, 4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening
-
Liu, X.; Xie, H.; Luo, C.; Tong, L.; Wang, Y.; Peng, T.; Ding, J.; Jiang, H.; Li, H. Discovery and SAR of thiazolidine-2, 4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening. J. Med. Chem., 2010, 53 (6), 2661-2665.
-
(2010)
J. Med. Chem
, vol.53
, Issue.6
, pp. 2661-2665
-
-
Liu, X.1
Xie, H.2
Luo, C.3
Tong, L.4
Wang, Y.5
Peng, T.6
Ding, J.7
Jiang, H.8
Li, H.9
-
240
-
-
78149280763
-
Discovery and selectivity-profiling of 4-benzylamino 1-aza-9-oxafluorene derivatives as lead structures for IGF-1R inhibitors
-
Krug, M.; Erlenkamp, G.; Sippl, W.; Schächtele, C.; Totzke, F.; Hilgeroth, A. Discovery and selectivity-profiling of 4-benzylamino 1-aza-9-oxafluorene derivatives as lead structures for IGF-1R inhibitors. Bioorg. Med. Chem. Lett., 2010, 20 (23), 6915-6919.
-
(2010)
Bioorg. Med. Chem. Lett
, vol.20
, Issue.23
, pp. 6915-6919
-
-
Krug, M.1
Erlenkamp, G.2
Sippl, W.3
Schächtele, C.4
Totzke, F.5
Hilgeroth, A.6
-
241
-
-
80052023098
-
Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: A novel approach for overcoming resistance in anticancer treatment
-
Tandon, R.; Kapoor, S.; Vali, S.; Senthil, V.; Nithya, D.; Venkataramanan, R.; Sharma, A.; Talwadkar, A.; Ray, A.; Bhatnagar, P.K. Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: A novel approach for overcoming resistance in anticancer treatment. Eur. J. Pharmacol., 2011, 667 (1-3), 56-65.
-
(2011)
Eur. J. Pharmacol
, vol.667
, Issue.1-3
, pp. 56-65
-
-
Tandon, R.1
Kapoor, S.2
Vali, S.3
Senthil, V.4
Nithya, D.5
Venkataramanan, R.6
Sharma, A.7
Talwadkar, A.8
Ray, A.9
Bhatnagar, P.K.10
-
242
-
-
79955536242
-
Specific targeting of insulin-like growth factor 1 receptor signaling in human estrogen dependent breast cancer cell by a novel tyrosine-based benzoxazepine derivative
-
Chakravarti, B.; Siddiqui, J.A.; Dwivedi, S.K.D.; Deshpande, S.; Samanta, K.; Bhatta, R.S.; Panda, G.; Prabhakar, Y.S.; Konwar, R.; Sanyal, S. Specific targeting of insulin-like growth factor 1 receptor signaling in human estrogen dependent breast cancer cell by a novel tyrosine-based benzoxazepine derivative. Mol. Cell. Endocrinol., 2011, 338 (1-2), 68-78.
-
(2011)
Mol. Cell. Endocrinol
, vol.338
, Issue.1-2
, pp. 68-78
-
-
Chakravarti, B.1
Siddiqui, J.A.2
Dwivedi, S.K.D.3
Deshpande, S.4
Samanta, K.5
Bhatta, R.S.6
Panda, G.7
Prabhakar, Y.S.8
Konwar, R.9
Sanyal, S.10
-
243
-
-
30444446821
-
Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: An in vitro and in vivo study in the 5T33MM mouse model
-
Menu, E.; Jernberg-Wiklund, H.; Stromberg, T.; De Raeve, H.; Girnita, L.; Larsson, O.; Axelson, M.; Asosingh, K.; Nilsson, K.; Van Camp, B. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood, 2006, 107 (2), 655.
-
(2006)
Blood
, vol.107
, Issue.2
, pp. 655
-
-
Menu, E.1
Jernberg-Wiklund, H.2
Stromberg, T.3
de Raeve, H.4
Girnita, L.5
Larsson, O.6
Axelson, M.7
Asosingh, K.8
Nilsson, K.9
Van Camp, B.10
-
244
-
-
1642494838
-
Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth
-
Girnita, A.; Girnita, L.; del Prete, F.; Bartolazzi, A.; Larsson, O.; Axelson, M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res., 2004, 64 (1), 236-242.
-
(2004)
Cancer Res
, vol.64
, Issue.1
, pp. 236-242
-
-
Girnita, A.1
Girnita, L.2
del Prete, F.3
Bartolazzi, A.4
Larsson, O.5
Axelson, M.6
-
245
-
-
33644751770
-
The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells
-
Girnita, A.; All-Ericsson, C.; Economou, M.A.; Astr, K.; Axelson, M.; Seregard, S.; Larsson, O.; Girnita, L. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Clin. Cancer Res., 2006, 12 (4), 1383-1391.
-
(2006)
Clin. Cancer Res
, vol.12
, Issue.4
, pp. 1383-1391
-
-
Girnita, A.1
All-Ericsson, C.2
Economou, M.A.3
Astr, K.4
Axelson, M.5
Seregard, S.6
Larsson, O.7
Girnita, L.8
-
246
-
-
33745100153
-
The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection
-
Vasilcanu, D.; Weng, W.; Girnita, A.; Lui, W.; Vasilcanu, R.; Axelson, M.; Larsson, O.; Larsson, C.; Girnita, L. The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection. Oncogene, 2006, 25 (22), 3186-3195.
-
(2006)
Oncogene
, vol.25
, Issue.22
, pp. 3186-3195
-
-
Vasilcanu, D.1
Weng, W.2
Girnita, A.3
Lui, W.4
Vasilcanu, R.5
Axelson, M.6
Larsson, O.7
Larsson, C.8
Girnita, L.9
-
247
-
-
33947508482
-
ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents
-
Steiner, L.; Blum, G.; Friedmann, Y.; Levitzki, A. ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. Eur. J. Pharmacol., 2007, 562 (1-2), 1-11.
-
(2007)
Eur. J. Pharmacol
, vol.562
, Issue.1-2
, pp. 1-11
-
-
Steiner, L.1
Blum, G.2
Friedmann, Y.3
Levitzki, A.4
-
248
-
-
26244435227
-
Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells
-
Youngren, J.F.; Gable, K.; Penaranda, C.; Maddux, B.A.; Zavodovskaya, M.; Lobo, M.; Campbell, M.; Kerner, J.; Goldfine, I.D. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells. Breast Cancer Res. Treat., 2005, 94 (1), 37-46.
-
(2005)
Breast Cancer Res. Treat
, vol.94
, Issue.1
, pp. 37-46
-
-
Youngren, J.F.1
Gable, K.2
Penaranda, C.3
Maddux, B.A.4
Zavodovskaya, M.5
Lobo, M.6
Campbell, M.7
Kerner, J.8
Goldfine, I.D.9
-
249
-
-
38649115388
-
Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells
-
Zavodovskaya, M.; Campbell, M.J.; Maddux, B.A.; Shiry, L.; Allan, G.; Hodges, L.; Kushner, P.; Kerner, J.A.; Youngren, J.F.; Goldfine, I.D. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells. J. Cell. Biochem., 2008, 103 (2), 624-635.
-
(2008)
J. Cell. Biochem
, vol.103
, Issue.2
, pp. 624-635
-
-
Zavodovskaya, M.1
Campbell, M.J.2
Maddux, B.A.3
Shiry, L.4
Allan, G.5
Hodges, L.6
Kushner, P.7
Kerner, J.A.8
Youngren, J.F.9
Goldfine, I.D.10
-
250
-
-
34648841156
-
Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells
-
Meyer, G.E.; Chesler, L.; Liu, D.; Gable, K.; Maddux, B.A.; Goldenberg, D.D.; Youngren, J.F.; Goldfine, I.D.; Weiss, W.A.; Matthay, K.K. Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells. J. Cell. Biochem., 2007, 102 (6), 1529-1541.
-
(2007)
J. Cell. Biochem
, vol.102
, Issue.6
, pp. 1529-1541
-
-
Meyer, G.E.1
Chesler, L.2
Liu, D.3
Gable, K.4
Maddux, B.A.5
Goldenberg, D.D.6
Youngren, J.F.7
Goldfine, I.D.8
Weiss, W.A.9
Matthay, K.K.10
-
251
-
-
84877819575
-
-
U.S. 2009/0280112. November 12
-
Goldfine, I.R.A.D.; Youngren, J.F.; Campbell, M.J.; Maddux, B.A.; Kerner, J.A.; Ryan, C.J. Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells. U.S. 2009/0280112. November 12 2009.
-
(2009)
Inhibitory Effects of Nordihydroguaiaretic Acid (NDGA) on the IGF-1 Receptor and Androgen Dependent Growth of LAPC-4 Prostate Cancer Cells
-
-
Goldfine, I.R.A.D.1
Youngren, J.F.2
Campbell, M.J.3
Maddux, B.A.4
Kerner, J.A.5
Ryan, C.J.6
-
252
-
-
0344625376
-
Mevalonate deprivation impairs IGF-I/insulin signaling in human vascular smooth muscle cells
-
Martínez-González, J.; Viņals, M.; Vidal, F.; Llorente-Cortés, V.; Badimon, L. Mevalonate deprivation impairs IGF-I/insulin signaling in human vascular smooth muscle cells. Atherosclerosis, 1997, 135 (2), 213-223.
-
(1997)
Atherosclerosis
, vol.135
, Issue.2
, pp. 213-223
-
-
Martínez-González, J.1
Viņals, M.2
Vidal, F.3
Llorente-Cortés, V.4
Badimon, L.5
-
253
-
-
0030808048
-
Mevalonate-regulated mechanisms in cell growth control: Role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc
-
Dricu, A.; Wang, M.; Hjertman, M.; Malec, M.; Blegen, H.; Wejde, J.; Carlberg, M.; Larsson, O. Mevalonate-regulated mechanisms in cell growth control: role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc. Glycobiology, 1997, 7 (5), 625.
-
(1997)
Glycobiology
, vol.7
, Issue.5
, pp. 625
-
-
Dricu, A.1
Wang, M.2
Hjertman, M.3
Malec, M.4
Blegen, H.5
Wejde, J.6
Carlberg, M.7
Larsson, O.8
-
254
-
-
0034120198
-
Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewings sarcoma cells: Therapeutic implications
-
Girnita, L.; Wang, M.; Xie, Y.; Nilsson, G.; Dricu, A.; Wejde, J.; Larsson, O. Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewings sarcoma cells: therapeutic implications. Anti-Cancer Drug Des., 2000, 15 (1), 67-72.
-
(2000)
Anti-Cancer Drug Des
, vol.15
, Issue.1
, pp. 67-72
-
-
Girnita, L.1
Wang, M.2
Xie, Y.3
Nilsson, G.4
Dricu, A.5
Wejde, J.6
Larsson, O.7
-
255
-
-
14344264703
-
Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics-an update
-
Neckers, L.; Neckers, K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics-an update. Expert Opin. Emerg. Drugs, 2005, 10 (1), 137-149.
-
(2005)
Expert Opin. Emerg. Drugs
, vol.10
, Issue.1
, pp. 137-149
-
-
Neckers, L.1
Neckers, K.2
-
257
-
-
0024151897
-
The heat-shock proteins
-
Lindquist, S.; Craig, E. The heat-shock proteins. Annu. Rev. Genet., 1988, 22 (1), 631-677.
-
(1988)
Annu. Rev. Genet
, vol.22
, Issue.1
, pp. 631-677
-
-
Lindquist, S.1
Craig, E.2
-
258
-
-
35948977339
-
Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1? autocrine loop, and reduces orthotopic tumor growth
-
Lang, S.A.; Moser, C.; Gaumann, A.; Klein, D.; Glockzin, G.; Popp, F.C.; Dahlke, M.H.; Piso, P.; Schlitt, H.J.; Geissler, E.K. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1? autocrine loop, and reduces orthotopic tumor growth. Clin. Cancer Res., 2007, 13 (21), 6459-6468.
-
(2007)
Clin. Cancer Res
, vol.13
, Issue.21
, pp. 6459-6468
-
-
Lang, S.A.1
Moser, C.2
Gaumann, A.3
Klein, D.4
Glockzin, G.5
Popp, F.C.6
Dahlke, M.H.7
Piso, P.8
Schlitt, H.J.9
Geissler, E.K.10
-
259
-
-
67650930911
-
Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer
-
MOSER, C.; Lang, S.A.; Stoeltzing, O. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer. Anticancer Res., 2009, 29 (6), 2031.
-
(2031)
Anticancer Res
, vol.29
, Issue.6
, pp. 2009
-
-
Moser, C.1
Lang, S.A.2
Stoeltzing, O.3
-
260
-
-
84863239500
-
Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: Structural insights, chemical diversity and molecular evolution
-
Jin, M.; Wang, J.; Buck, E.; Mulvihill, M.J. Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution. Future Med. Chem., 2012, 4 (3), 315-328.
-
(2012)
Future Med. Chem
, vol.4
, Issue.3
, pp. 315-328
-
-
Jin, M.1
Wang, J.2
Buck, E.3
Mulvihill, M.J.4
|